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ABSTRACT
Electroconvulsive therapy is used to treat the acute depression and chronic 
depression, resistant to pharmacological therapy .
Objective:This study was done to compare the effects of esmolol and labetalol in 
attenuation of hemodynamic responses after ECT.
Materials and methods:90 patients aged 18-60 years were randomly divided into 
three groups. Baseline parameters were recorded .Group C received 5 ml of normal 
saline ,group E received 1mg/kg esmolol and group L received 0.25mg/kg 
labetalol after induction. Heart rate, systolic BP and diastolic BP were recorded at 
1min after test drug administration and 1,3,5,10 minutes after ECT .Hypertension 
and tachycardia occurred due to sympathetic nervous system activation after ECT. 
Results:It was found that esmolol significantly attenuated the degree of 
tachycardia and hypertension, in the first three minutes compared to placebo 
whereas the rise in HR and blood pressure was significantly reduced in the 
labetalol group in comparison to placebo, from three minutes to ten minutes.
Conclusion:It was concluded that esmolol is effective in blunting the 
hemodynamic responses in the first three minutes after application of the electrical 
current, whereas Labetalol is effective from five minutes to ten minutes after ECT.
Key words: Electroconvulsive therapy, hemodynamic responses, esmolol,
labetalol, sympathetic nervous system.
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INTRODUCTION 
 Electroconvulsive therapy (ECT) was introduced in the 1930s to treat 
schizophrenia.Use of Electroconvulsivetherapy decreased through the 1970s 
because of negative publicity.Acceptance and use of ECT have again 
increased. Currently Electroconvulsive therapy is accepted due to the 
administration of general anesthesia to decrease the physical and 
psychological trauma associated with ECT.ECT consists of programmed 
electrical stimulation of the central nervous system to initiate seizure 
activity.The exact mechanism of the therapeutic effect of ECT remains 
unknown.ECT causes changes in chemistry of the brain, that will reverse the 
symptoms of the psychiatric disease.It is used in conditions where other 
modalities of treatment fails. Electroconvulsive therapy was developed in 
1938.ECT is effective in treating many psychiatric illness,especially 
depression. Patients with severe depression resistant to pharmacological 
treatment and intolerable to the side effects of psychiatric drugs can also be 
treated with ECT.ECT is the treatment of choice for patients who need a 
rapid response.This includes those who are severely agitated,having delusion 
and suicidal tendency,refuse to take food and water,as well as catatonic 
condition.  
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 ECT is also used as a mood stabilizer during the episodes of mania or 
depression in bipolar disease.Electroconvulsive therapy is useful in treating 
the psychotic episodes associated with schizophrenia. 
 In ECT,patients received high doses of electric current without 
anesthesia in older days,lead to vertebral or long bone fractures due to violent 
muscle contractures,short term memory loss, and other serious side effects. 
 ECT is performed under general anaesthesia now a days.People who 
have psychiatry illness can safely undergo ECT.Although ECT still causes 
some side effects,it now uses electrical currents given in a controlled setting 
to achieve the benefits with the fewer side effects. 
 Anaesthesiologist’s aim is to provide safe and effective anaesthesia 
without interfering the beneficial effects of ECT in psychiatric 
patients.Activation of central nervous system during ECT leads to release of 
catecholamine which leads to increase in the blood pressure and heart 
rate.This physiological  effects of  ECT  leads to infarction or ischemia or 
even stroke  in patients with preexisting cardiac and cerebrovascular 
disease.Many drugs are used by various routes in attenuating the 
physiological responses during ECT.  
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 In this study comparison of  Esmolol and labetalol in attenuation of 
hemodynamic responses after ECT in the immediate period to ten minutes 
was done.Esmolol is an ultrashort acting beta1selective adrenergic blocker 
where as Labetalol is a combined alpha 1 and beta blocker.It has alpha 1and 
predominant beta adrenergic receptor blocking activity.In intravenous route 
alpha:beta action is 1:7 whereas in oral route is 1:3.There are studies to 
evaluate the efficacy of these drugs to attenuate the hemodynamic responses 
to ECT. 
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AIM & OBJECTIVES OF THE STUDY 
To compare the effects of Esmolol and labetalol in attenuation of  
hemodynamic responses after ECT. The comparison of effects of these drugs 
was done by monitoring and comparing the following parameters 
· Baseline heart rate, systolic and diastolic BP 
· Heart rate, systolic and diastolic BP at 1 min after administration of the 
test drug. 
· Heart rate, systolic and diastolic BP at 1,3,5,10 minutes after ECT 
PRIMARY OBJECTIVE : 
 To study the effects of Esmolol and Labetalol in attenuation of 
hemodynamic responses after ECT. 
SECONDARY OBJECTIVES : 
 1) To study the hemodynamic effects after ECT. 
 2) To compare the effects of Esmolol and Labetalol in attenuating the   
  hemodynamic responses after ECT.  
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HISTORY 
 April 2013 saw the 75th anniversary of the first use of 
Electroconvulsive Therapy (ECT), making it the oldest surviving physical 
treatment in Psychiatry. In 16 th century, the Swiss physician Paracelsus 
(Auroleus Phillipus Theostratus Bombastus von Hohenheim) treated 
psychiatry patients by inducing seizures by giving camphor orally where as in 
1934, the Hungarian neuropathologist Ladislas Joseph von Meduna began the 
modern era of convulsive therapy by giving camphor intramuscularly (soon 
replaced with pentylenetetrazol) in treating catatonic schizophrenia. The 
electrical stimulation of a series of seizures in catatonic patient was first done 
by an Italian psychiatrist Lucio Bini and neurologist Ugo Cerletti in 1938 and 
produced a successful response.In United States ECT was introduced at 1939.  
Fractures and dislocations are more in unmodified ECT .Curarae was used as 
a relaxant in ECT in 1940.In 1950s antipsychotic drugs were not 
developed.Insulin shock and lobotomy were used as an effective alternative 
for ECT.  
 Max Fink was the first to apply rigorous scientific research methods in 
1950s. Suxamethonium as identified in 1951 and in 1958 controlled study on 
unilateral ECT was done. In 1960s,randomized control study was done to 
compare the effects of  ECT in treating depression with pharmacological 
treatment. 
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 It showed increased response rates in ECT.If  the patients fear 
suffocation after giving muscle relaxants anaesthetists used to give some 
short acting anaesthetic drugs.In Britain most hospitals used unmodified ECT 
routinely by the mid 1950s.In 1957 at a London hospital, a patient had 
sustained fractures to both hips when undergoing unmodified ECT.He took 
legal action against hospital.The First Task Force Report was published by 
the American Psychiatric Association in 1978 on ECT,had the goal of 
establishing standards for consent and the technical and clinical aspects of the 
conduct of ECT.In 1985,the National Institutes of Health and National 
Institute of Mental Health Consensus Conference on ECT endorsed a role for 
the use of ECT and advocated research and national standards of practice. 
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MECHANISM OF ACTION OF ELECTROCONVULSIVE THERAPY 
   NEUROTRANSMITTER THEORY 
   NEUROENDOCRINE THEORY 
   ANTI CONVULSANT THEORY 
   BRAIN DAMAGE THERAPY 
   PSYCHOLOGICAL THEORY 
Mechanism of action 
 The exact mechanism of action of ECT is not known fully. 
Electroconvulsive therapy affects all the components of central nervous 
system, including neuropeptides, neurotrophic factors, harmones and 
neurotransmitters.  
  Bilateral generalized seizure is needed for the beneficial and adverse 
effects of ECT.Seizure threshold raises during ECT by increasing GABA 
transmission and antagonism of receptors. Endogenous opioids are also 
increased during ECT. It also has the anticonvulsant properties. The 
neurophysiological effects of ECT is studied by Positron emission 
tomography. After ECT there will be reduction in glucose metabolism in 
bilateral anterior and posterior frontal areas represented the most consistent 
findings.  
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 ECT affects all neurotransmitter system including serotonin, 
muscarinic, cholinergic,dopaminergic,beta-adrenergic systems. Brain-derived 
neurotrophic factor (BDNF), catechol-O-methyl transferase (COMT) second-
messenger systems may play an important role in ECT. 
Indications 
 ECT is used to treat the psychiatric disorder like schizophrenia, 
depressive disorder, bipolar disorder, and other psychiatric  disorders. 
Major depressive illness 
  In the acute phase of major depressive illness, patients have functional 
impairement, psychotic symptoms, high degree of severity of symptoms and 
catatonia.They are considered to undergo ECT.ECT may also useful in 
treating patients in whom response to the treatment is needed urgently, who 
are nutritionally compromised due to poor food intake or patients who have 
suicidal tendency. 
Bipolar disorder 
  Patients with severe or treatment resistant mania or mixed episodes 
of bipolar disorder, or for patients who prefer this treatment modality(after 
consulting with the psychiatrist) may be considered to undergo ECT.Mania is 
charecterized by hyperactivity, intense euphoria and agitation that occurs as 
part of bipolar disorder. Other signs of mania include impulsive or risky 
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behavior, impaired decision making, psychosis and substance abuse.ECT is a 
potential treatment for pregnant patients having depression or severe 
mania.ECT is beneficial in treating the patients with rapid cycling bipolar 
disorder.Earely mania results from ECT.  
 ECT is also used as an alternative for the patients with life-threatening 
inanition (an exhausted condition due to poor intake of food and water), 
suicidal tendency or psychosis.ECT should also be considered in patients  
having depression with psychotic or catatonic features. Maintenance ECT is 
useful in patients who have acute episode of depression.  
Schizophrenia 
 ECT is effective in treating the symptoms of acute schizophrenia but is 
not useful in treating chronic schizophrenia. Severe psychosis patients who 
have not responded to treatment with pharmacological agents like psychiatric 
medications may be considered to undergo ECT. When ECT is administered 
along with antipsychotic medications therapeutic beneficial is very 
good. ECT also should be considered for patients with prominent catatonic 
features like lack of speech, lack of movement, strange or fast movements 
and other symptoms.Schizophrenia is also associated with some other 
psychiatric disorders.In some cases,catatonia is caused by a medical illness.  
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 Patients who have not responded to lorazepam can also undergo 
ECT.In depression patients ECT may be beneficial in patients having 
treatment resistant depressive symptoms or if features such as suicidal 
thoughts occur. 
 In the stable phase of schizophrenia, ECT may be beneficial in some 
patients who has response to ECT in the acute phase but not responded to  
pharmacological prophylaxis alone or who cannot tolerate that.ECT is also be 
effective when marked positive and affective symptoms are present.  
Other psychotic disorders 
 ECT is effective in patients who have psychotic disorders related to 
schizophrenia, such as schizophreniform disorder and schizoaffective 
disorder. In combination with antipsychotics, ECT may also be considered 
for patients with schizoaffective disorder with severe psychosis that has not 
responded to treatment with antipsychotic medications.  
Comorbid disorders 
 ECT is not usually recommended in treating obsessive-compulsive 
disorder(OCD) but may be considered in the treatment of comorbid disorders 
such as major depressive disorder, mania, and schizophrenia in patients with 
OCD.  
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Other disorders and indications 
 ECT will be effective in treating the patients with catatonia,  neuroleptic 
malignant syndrome,  depression associated with Parkinson disease,pain,and 
acute confusion psychosis.It is also used in the treatment of patients with 
intellectual disabilities who have treatment resistant mood or psychotic 
disorders.  
 ECT may be useful in patients with major depressive disorder . In 
some patients pharmacological treatment or psychotherapy has not been 
effective in maintaining stability during the continuation phase.In these 
patients we may consider  ECT.. 
  In some cases ECT is also used in special conditions like pregnancy, 
when medications can't be taken for the benefit of fetus, older patients who 
can't tolerate the side effects of drugs,in  people who prefer ECT treatments 
over pharmacological treatment,when ECT has been successful in the past. 
Patients with melancholic and atypical depression can also be treated with 
ECT. 
SIDE EFFECTS 
 ECT is generally safe,but it also has following risks and side effects  
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Confusion. 
 After treatment patients may have confusion for a short period even it 
may last from a few minutes to several hours.patients  may not know where 
they  are and why they are.Patients return to normal activities after some 
hours of  rest after ECT,rarely confusion may last for several days or 
longer.Confusion is more in older patients than young adults. 
Memory loss.  
 ECT will also cause memory loss in many way.Patients may not 
remember events that occurred before treatment began, a condition known as 
retrograde amnesia. It is very difficult to recall the events in the weeks or 
months leading up to treatment.Some people may have problems with 
memories from previous years,as well.Patients may not recall the events that 
occurred during the weeks of the treatment.And some people have trouble 
with memory of events that occur even after ECT has stopped. Usually these 
memory problems  may be  improved  within 2 months. 
Physical side effects 
 Patients may have headache,nausea,vomiting,pain in the jaw,myalgia 
and spasm of the muscles.They are treated by supportive medications. 
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Medical complications. 
 During ECT, heart rate and blood pressure raises due to sympathetic 
responses. Patients who have cardiac diseases like coronary artery disease, 
and people who have hypertension, diabetis mellitus ,sinus tachycardia are at 
risk. Potential arrhythmias like ventricular tachycardia, atrial fibrillation. 
Diabetic patients may have silent ischemia so they have more risk.  
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PROCEDURE 
 
Preparation 
 
Anesthesia 
 Initially ECT was performed without anaesthesia.After 1950 ECT was 
performed under anaesthesia.The goal is to achieve a light level of 
anaesthesia. Drugs used in 
 ECT are barbiturates like Methohexital and Thiopentone 
sodium,ketamine hydrochloride,Etomidate,Alfentanyl,Propofol.Methohexital 
is commonly used in ECT as it is safe and efficacy is good and it is 
cheap.Inhalational agents such as sevoflurane. The cognitive outcome after 
ECT depends upon the anaesthetic medication not the choice of agents but 
the dosage.Appropriate dose should be assessed and adjusted with that dose 
in subsequent treatments.  
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Equipment 
 The ECT treatment and recovery room  should contain a monitor with 
pulseoxymetry, BP cuff, ECG electrodes, Oxygen delivering system. 
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Positioning 
 Common electrode positions in ECT electrodes are placed in right 
unilateral,bifrontotemporal, and bifrontal positions.Electrodes are placed 
bifrontotemporally, with the center of each electrode approximately 1 inch 
above the midpoint of an imaginary line drawn from the tragus to the external 
canthus in the bifronto temporal position(bilateral position). In case of right 
unilateral position, one electrode is placed on the nondominant fron to 
temporal area, and the other electrode is placed over the nondominant 
centroparietal scalp, just lateral to the midline vertex.  
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 In most of the people, unilateral electrode placement is always over the 
right hemisphere,because of the left hemisphere dominance. 
 Electrode is placed more frontally on each side of the head in bifrontal 
position  than in standard bifrontotemporal placement.In asymmetric bilateral 
position, the left electrode is moved about 6 cm anterior from the standard 
frontotemporal position, and its lateral edge is medial to the bony intersection 
ridge between the temple and the forehead. The right electrode is in 
frontotemporal position. 
 
 
 
(A)Bilateral ECT(Bitemporal electrodes). (B) Unilateral ECT. 
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Pre-treatment Evaluation 
  Pre ECT evaluation must include: 
 History, cardiovascular and respiratory system examination, cognitive 
assessment and other systems examination. Laboratory investigstions 
includes complete hemogram, Serum biochemistry, renal function tests 
,ECG,X-ray chest. Consultation with cardiologist, neurologist, 
neurosurgeon, or endocrinologist as needed by special conditions. 
Informed Consent 
 In ECT written informed consent is an important part. This should be 
documented in the patient's medical record and should include a discussion of 
the disease,course,and the option of receiving treatment.The family members 
should participate in that discussion and consent should be obtained from the 
family members.  
 
Electroconvulsive Therapy with Comorbidity 
 Assosciated comorbid conditions and their treatments may affect the 
response to and risks associated with electroconvulsive therapy. 
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Neurological diseases 
 Should be cautious with the patients having space occupying intra 
cranial tumors.ECT treatment may result in brain edema and 
herniation.Patients with intracranial pathology without mass effect can 
undergo ECT safely.As ECT increases the blood flow to the brain it increases 
intracranial pressure.Risk during ECT increased in patients with increased 
intracranial pressure or with cerebrovascular disease and  cerebral aneurysms.  
Cardiac diseases 
 Patients who have cardiac disease should undergo thorough evaluation 
before ECT.Patients who have unstable angina,uncompensated congestive 
heart failure, uncontrolled hypertension, atrioventricular block more than 
second degree and symptomatic ventricular arrhythmias are at 
risk.Hypertension should be controlled with antihypertensives before going to 
ECT. Patients with a recent myocardial infarction (MI) are at high risk of 
cardiac complications failure,after 2 weeks of MI risk is reduced and after 3 
months of MI risk is further reduced.Patients with cardiac pacemakers and 
implantable cardioverter defibrillators can safely undergo ECT with a proper 
pre-ECT cardiac and pacemaker/defibrillator assessment.ECT can also be 
used in the presence of severe aortic stenosis. 
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Other comorbidities 
 Patients who require more work up and close monitoring during ECT 
are patients with diseases such as pheochromocytoma,  hyperthyroidism, or 
with sensitivity to anesthesia like pseudo cholinesterase deficiency, 
 amyotrophic lateral sclerosis, porphyria,or with cognitive sensitivity 
as traumatic brain injury. Due to the stimulation of vagus nerve gastro 
esophageal reflux disease may worsen during ECT. Other patients require 
close monitoring are patients with diabetes, metabolic disorders such as 
hyponatremia, hyperkalemia, hypokalemia, COPD, hypercoagulable states, 
renal disease and glaucoma. 
Electroconvulsive Therapy and drugs 
 Drugs like antiarrythmics, antihypertensives, antianginals, 
bronchodilators, glaucoma drugs, and steroids can be given prior to ECT 
safely.Proton pump inhibitors and H2 blockers can also be used. 
  Hypoglycemics and diuretics must be withheld until ECT treatment. If 
possible patient should discontinue theophylline.As  antiepileptics may raise 
the seizure threshold, may affect the clinical efficacy of ECT.Anticonvulsant 
dose should be reduced during ECT. 
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  Monoamine oxidase inhibitors (MAOIs) can also be used safely. 
Before 7-14 days some clinicians may withhold MAOIs.When  ECT is more 
effective when combined with antipsychotic drugs in schizophrenia than 
either treatment alone.Combination of ECT and antipsychotic drugs is safe 
and effective in refractory schizophrenia. 
 Use of  lithium during ECT usually has no problems but some patients 
will have the risk for delirium or duration of seizures may be 
prolonged. Benzodiazepines dose should be reduced or if possible 
discontinued.ECT can also be given in combination with antidepressants 
safely.High doses of  Bupropion can be used with caution.  
Electroconvulsive Therapy in the Elderly  
 More number of patients who receive ECT belongs to the geriatric age 
group. ECT is useful in treating catatonia in geriatric patients,and also in 
psychotic disorders and mania in bipolar disorder.Usually, geriatric patients 
with depression responds well to ECT than young adults. ECT is indicated in 
patients with depression associated with psychosis,suicidal tendency, or 
severely malnourished,it is also helpful in treating treatment resistant 
nonpsychotic major depression. 
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 Seizure threshold also rise in geriatric patients,and difficult to induce effective seizures. During and after ECT geriatric patients are at higher risk for persistant confusion and greater memory deficits.A 2003 Cochrane Database review of ECT for elderly patients with depression found that solid conclusions could not be drawn as to whether ECT was more effective than antidepressants or regarding the safety and adverse effects of ECT in these patients. 
Electroconvulsive Therapy in Pregnancy 
 During pregnancy ECT is safe and its efficacy is good for the mother 
in treating the major depressive illness during pregnancy.ECT is also more 
potent in treating severe manic episodes of  bipolar and also in severe 
depression.It is also used in pregnancy in patients who do not want to take the 
pharmacological treatment to avoid the exposure of psychiatric drugs or those 
who are resistant to standard drug therapy.Before going to ECT patient 
consult the obstretician and monitoring of the fetus should be done as 
needed.Patients in the third trimester should not lie in the supine 
position.They should turn to left during ECT.It avoids the compression of the 
great veins and allows more blood to the fetus otherwise fetal hypoxia may 
occur.Avoidence of hyperventilation is necessary. 
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 Anesthesia drugs minimally crosses the maternal fetal barrier.As ECT 
does not cause teratogenicity and neonatal toxicity it is considered as a safe 
procedure.Pregnancy should be considered as full stomach always.So 
pregnant women have the increase risk of aspiration due to increased 
gastroesophageal reflux.So they are premedicated with sodium citrate which 
is called non particulate antacid.ECT is also relatively safe in breast feeding 
mother.Anesthetic drugs have minimal risk to the nursing infant.If the 
nursing mother delays feeding for few hours after an ECT treatment the drug 
exposure is minimal.Lactating women can use the expressed breast milk after 
ECT and it can be collected in the bottle before ECT.   
Conduct of anaesthesia 
 Check the consent and ask for starvation and administration of regular 
medicines before ECT.Emergence may delay when sedatives are used and 
duration of seizure may be altered.As the ECT may cause urinary 
incontinence ask the patient to empty the bladder before ECT.Many of the 
anaesthetic drugs have anticonvulsant properties.The choice of anaesthetic 
agents should provide anaesthesia without affecting the efficacy of ECT. 
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Pretreatment sedation 
 Pre ECT sedation is given to relieve the anxiety.Sedative drugs are 
given in some patients before first ECT to reduce the awarness and make the 
patient calm. The sedatives can be given intramuscularly as oral is not 
allowed.Drugs having anti convulsant properties should be avoided.As drugs 
like barbiturates and benzodiazepines have anticonvulsive effects they are 
counter productive.It is difficult to judge the efficacy of ECT in patients who 
are taking  potent neuroleptics as it may obscure the clinical signs.In patients 
with depression or mania,clinical signs and symptoms may be masked by 
potent neuroleptics.So it is difficult to judge the effectiveness of the course of  
the ECT.Therefore 25-30 mg of promethazine or 2.5-5 mg of droperidol or 
hydroxyzine given intramuscularly, are useful because these sedatives 
enhances seizure activity without affecting the seizures. 
Anticholinergics 
 Bradycardia occurs for a short period after the application of electric 
current in ECT,which is followed by tachycardia.It corresponds to the seizure 
activity.Before induction administration of the anticholinergics like 
glycopyrrolate or atropine will reduce the incidence of bradyarrythmias and 
asystole.It is also used to reduce the airway secretion and it dries the 
secretions there by it reduces the risk of bronchospasm. 
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 In patients taking beta-adrenergic receptor blockers anticholinergics 
may be useful.Due to lack of an evidence base in altering the cardiovascular 
effects of ECT, anticholinergics were not used by all physicians. 
Anticholinergics may increase preexisting tachycardia and it may cause 
urinary retention, constipation, fecal impaction. 
Induction agents 
 Many intravenous anesthetics have been used to induce anesthesia for 
ECT, including methohexital, thiopental, propofol, and ketamine.Dosage of 
inducing  drugs is titrated according to the patient weight it can be modified  
as needed depending on any changing seizure thresholds and previous 
response to ECT. Compared with other barbiturates.Methohexital has 
minimal anticonvulsant properties.Previously the drug was not available.So 
other hypnotic drugs were used.Now it is used as a gold standard 
drug.Etomidate dose of 0.15-0.3mg/kg produces seizures,but others don’t.It 
has disadvantages like nausea and vomiting,more hemodynamic changes and 
recovery may be slow.It may also cause adreno cortical suppression.Propofol 
can be used as it will not affect the seizure quality.It will be used in the 
dosage of 1-2mg/kg.Thiopentone is also used because of its 
availability.Usually ketamine is not used because it increases intracranial 
hypertension and emergence.  
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 Etomidate can also be used as i.v. inducing drug that may decrease the 
threshold of seizures.Opioids such as remifentanil (1 mg/kg over 30–60 
seconds) or alfentanil (10–25 mg/kg) can be given in combination with 
inducing agents other than etomidate.Whatever drug is used, It is adviceable 
to use the same drug used in the initial treatment throughout course of 
treatment to avoid interfering with the seizure threshold (which generally 
increases over a course of ECT). For induction Sevoflurane 6–8% inspired 
concentration can also be used.It reduces the duration of seizures when 
compared with methohexitol. It can be used as an inducing agent when 
venous access is difficult.It reduces the contraction of uterus  in 
pregnancy.Disadvantages are more time consuming and equipment needed. 
Neuromuscular blocking agents 
 Because of the impedence of the monitoring of peripheral seizure 
duration,it is not necessary to block neuromuscular junction completely it is 
also not desirable.Partial neuromuscular blockade is necessary,to reduce the 
peripheral manifestations of the seizure and to prevent musculoskeletal 
trauma to the patient. Neuromuscular junction blocking agents reduces the 
muscular contractures. There by it reduces the risk of serious 
injuries.Complete blockade of neuromuscular system is needed in high risk 
patients having osteoporosis which may produces fractures of long bones or 
vertebra during ECT,or a history of injury to the spine. EEG monitoring is 
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very useful in monitoring the seizure activity and also visible muscle activity 
more accurately,when complete relaxation needed.Most commonly used drug 
to produce neuromuscular blockade is Succinylcholine in the dosage of 0.5 
mg/kg.In cases of preexisting skeletal injury,severe osteoporosis and severe 
cachexia large dose up to 1.5 mg/kg may be needed.Non depolarizing 
neuromuscular blocker can be used if suxamethonium is 
contraindicated.Mivacurium is a short acting neuromuscular blocking 
agent.But ,modification of the seizures is not sufficient with low doses (0.08 
mg/ kg) of Mivacurium,so lowest dose should be 0.15 mg/kg.Vecuronium 
and rocuronium is used as precurarizing agents but these drugs can be used 
with the advent of sugammadex. Nondepolarizing neuromuscular blocker is 
indicated in patients with severe hypercalcemia, severe osteoporosis, severe 
neuromuscular disease, pseudocholinesterase enzyme deficiency, and patients 
having previous history of malignant hyperthermia or in the family members. 
 Prior to electrical current stimulation, the reduction or loss of knee, 
ankle, and plantar withdrawal reflexes shows the adequacy of muscle 
relaxation. Loss of muscular tone, the decreased response to a nerve 
stimulator or any combination of these factors can also shows the adequacy 
of muscle relaxation. 
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Adjuncts 
 Some drugs can be added in high risk patients to lower the dose of 
inducing agent or commonly to attenuate the hemodynamic 
responses.Parasympathetic side effects may be dimnished with the use of 
atropine or glycopyrrolate.As glycopyrrolate lacks the adverse effects of 
central nervous system it can be used as an anti-sialogogue and it reduces the 
tachycardia after ECT.Atropine is avoided as premedicating agent as it 
increases myocardial work and oxygen demand.Atenolol given before ECTor 
short acting beta blockers like esmolol used intra procedurally prevents 
adverse sympathetic effects.Calcium channel blockers is also used to control 
blood pressure effectively.Nifedipine is used sublingually and nicardipine 
used IV to reduce the BP,but it causes reflex tachycardia.Diltiazem is also 
used to decrease BP.Alpha2 agonists  like dexmedetomidine is also used to 
attenuate the hemodynamic responses. Glyceryl trinitrate should be used to 
reduce the risk of myocardial ischemia and infarction in patients at high 
risk.There is no role in the use of  intravenous lignocaine. 
Airway management 
 Patient should be pre oxygenated with 100% oxygen.Endotracheal 
intubation is not routinely needed unless patient has the risk of aspiration as 
in pregnancy and obesity.Ventilation can be assisted with face and mask. 
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 After induction, face and mask ventilation can be continued to assist 
the respiration.As hyperventilation reduces seizure threshold and may 
prolong duration of seizures it should be avoided.Patient’s tongue,lips and 
teeth should be protected by inserting the bite block.Ventilation should be 
assisted gently during the procedure until breathing resume.Magnitude of the 
stimulus will be titrated during initial sessions until an adequate seizure is 
generated.In this situation further doses of inducing agent are needed for the 
maintenance of anaesthesia. 
Postoperative considerations  
 Standard monitors are attached during recovery and should supply 
oxygen untill saturation maintains in room air.Early recovery makes 
discharge faster according to the standard criteria.Reassurance is more 
important. Commonly facing side effects are violent behaviour, agitation, 
confusion,amnesia, headache, nausea and vomiting myalgia,heamodynamic 
complications may exist at this stage.The most difficult problem to face is 
emergence agitation.Minimal dose of midazolam can be used as simple 
measure. 
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Physical and psychological needs of the patient 
 Routine follow up in electroconvulsive therapy is mandatory  to 
conclude both hemodynamic responses to ECT and to note down the side 
effects scheduled above in order to prevent, reduce,and treat the 
problem.Some patients may elicit an intense fear of treatment,as a rare 
psychological effect. Reassurance is mainstay to reduce the adverse effects of 
treatment. 
Special considerations 
Cerebral aneurysm 
 An increase in the wall stress of aneurysm may lead to rupture or 
enlargement of aneurysm.During ECT thiopentone increases the cerebral 
blood flow more when compared to propofol.So propofol can be used 
safely.Beta blockers and Sodium nitroprusside can inhibit the increase of 
aneurysm. 
Intracranial mass lesions 
 Admininistration of steroids and diuretics before ECT reduces the 
intracranial pressure.Hyperventilation may be beneficial when applied before 
ECT. 
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Pacemakers or implantable defibrillators . 
 Due to high tissue resistance only small amout of electric current 
reaches the device.so,risk is low.Pacemaker activity may be triggered by 
skeletal muscle contractions during tonic clonic seizures.Temporary 
conversion to fixed rate pacing is usually recommended prior to ECT.Internal 
cardioverter defibrillators should be deactivated prior to ECTand reactivated 
in the early recovery period. 
Neuroleptic malignant syndrome 
 Some antipsychotic medicines produce very serious side effects like 
neuroleptic malignant syndrome as similar with malignant hyperthermia.It is 
presented with fever,muscle rigidity,elevated creatinine levels,delirium and 
autonomic instability. 
  As halothane and succinylcholine trigger Malignant Hyperthermia 
they should be avoided. 
Pregnancy 
 As pharmacotherapy may produce teratogenicity ECT is to be 
considered as a safe and effective form of treatment in pregnancy.It may 
increases the risk of aspiration in the mother and also spontaneous abortion 
and preterm labour. 
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 If patient has history of preterm labour tocolytic drugs should be given 
before ECT.Sevoflurane used for the maintenance in third trimester 
pregnancy will decrease the risk of uterine contractions. 
Consent 
 The consent should be taken in writing  from the patient, or their 
relatives as the case may be ,before the start of the treatment.Some centres 
believe in renewal of consent after every treatment.The following points must 
be considered while obtaining the consent. 
 I. Adequate information must be given regarding the procedure, the 
expected benefits, side effects and complications. Discussion must be at this 
stageso as to allow clarifications of any doubts or apprehensions that the 
patients or the family members have. 
 II.The patient should be aware of his/her right to refuse treatment 
before or at any time during the ECT course. 
 III.Pat ient should be aware of the balance of advantages and 
disadvantages of the available treatment options. 
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TECHNIQUE 
Overview 
 The electrical current stimulus must be sufficient to induce a seizure. 
In modern electroconvulsive therapy machines a brief pulse wave form is 
used.The dose of discharged charge can be measured in millicoulombs. Three 
methods are used to determine Stimulus intensity and dosing can be 
determined by Empirical titration, Formula based titration,and Fixed 
dosages.Progressively higher doses of electric current are given in empirical 
titration,until seizure threshold is reached during the first session of 
ECT.Seizure threshold is determined by this method accurately. The dose is 
determined by some factors like age,sex, and placement of electrodes in 
formula based titration.Independent of patient or other factors,a fixed dose is 
given in the third method. A fourth method, in which intensity of the stimulus 
is increased progressively during delivery from a subconvulsive to a 
convulsive level,called the glissando technique,is not used. When 
determining intensity of stimulus, changes in threshold of seizures and dosing 
during the treatment course should also be considered. Threshold of seizure 
may increase in ECT. 
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Quality of the Seizures 
 Duration of seizures has minimal effect on the efficacy of 
electroconvulsive therapy, and seizure duration is associated with intensity of 
the stimulus. When the electrical stimulation is inadequate it may result in 
limited seizures. It is manifested by duration of seizure less than 15 seconds 
in EEG. 
 Confirmation of seizure activity and documentation of  seizure 
duration can be done with the use of EEG. The "cuff" procedure is used to 
monitor seizures motor activity, in which distribution of a muscle relaxant is 
blocked to the hand or foot by using a tourniquet to maintain the potential for 
muscle contraction. 
Treatment Frequency 
 ECT is given 3 times per week in the United States regardless of the 
placement of electrode. Usually frequent regimens of ECT is not 
recommended. Memory impairment is less when treatment is given two times 
per week compared with treatments three sessions per week.  Same degree of 
the final clinical improvement is seen in patients receiving ECT three times a 
week when compared with patients receiveing ECT two times a week, 
although possibly at a slow response rate. 
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 More than one adequate seizure is induced under anaesthesia, in the 
same session in Multiple monitored ECT(MMECT).Neuroleptic malignant 
syndrome, an urgent clinical condition may need MMECT,it is not 
recommended usually. 
Number of ECT 
 The number of treatments needed to achieve a full clinical response in 
patient varies widely.Usually 6-12 treatments is enough to show the 
response.After a few treatments some patients show response,and some may 
not show response even after ten sessions of ECT.The number of treatments 
depends upon the function of the degree of the illness,and the rate of 
improvement of the clinical symptoms and signs,as well as the degree of 
cognitive side effects.  
Treatment Complications 
 The main complications of electroconvulsive therapy are cognitive 
adverse effects and mortality. 
Cognitive side effects 
 Major side effects during ECT are cognitive side effects.The severe 
side effects occurs postictally after ECT,with impairement of memory,praxis 
and attention and a brief period of disorientation. 
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 These effects may be reversed.Severity and extent of cognitive side 
effects may vary significantly in individuals after ECT.Various 
electrophysiological studies,neuroimaging,and biochemical studies,correlates 
the adverse effects of ECT on cognitive function may exist. 
 Occurance of  Cognitive deficits depends on the ECT technique.In this 
situation the technique of ECT can be modified and can switch over to 
unilateral technique.Cognitive side effects may be increased when lower the 
stimulus dose, stopping medications and increasing the time interval between 
treatments. 
 After ECT anterograde and retrograde amnesia may occur. Rapid 
recovery is seen in antegrade amnesia.Deficits for events closest to the 
treatment time occurs in retrograde amnesia. In some patients delirium occurs 
postictally. 
 A prospective,longitudinal study of clinical and cognitive outcomes in 
patients treated with ECT for major depression was done. Patients were 
treated at 7 facilities and study was done.It was found that outcome of 
cognitive and clinical functions varied across facilities. These differences 
mainly dependant on the ECT technique.  A recent review in older patients it 
was found that older adults show mixed responses regarding the impact of 
ECT on cognitive function. 
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Mortality 
 Most common causes of the mortality during ECT are Cardiovascular 
complications and pulmonary complications.Patients undergoing ECT have 
the mortality rate of 1 in 10,000 patients and it is 1 in 80,000 in patients 
undergoing treatments.This mortality rate is about the same as that associated 
with minor surgeries.Patients with severe medical disorders may have the 
higher mortality rate when compared to patients with,tricyclic antidepressant 
therapy. 
Other adverse effects 
 Soon after the administration of ECT the patient may go for 
asystole.Patients receiveing medications that lower seizure threshold may 
have prolongation of seizure duration and also status epilepticus.Patients who 
metabolize succinylcholine slowly due to decreased level of 
pseudocholinesterases may go for prolonged apnea.Headache occurs 
commonly.It can be treated with drugs such as 
NSAIDS,acetaminophen,aspirin, sumatriptan,  and analgesics like codeine can 
be used rarely.Myalgia and nausea can occur.  Mania after ECT is rare. 
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PHYSIOLOGICAL RESPONSES TO ECT 
Cardiovascular effects 
 The effects of  ECT in the cardiovascular system occurs as a result of 
autonomic system.Starting with the electrical current stimulus,initially 
stimulates parasympathetic system which causes parasympathetic discharge 
primarily by stimulating the neurons of the hypothalamus to the vagal nerve 
resulting in  bradycardia,hypotension or even asystole lasts for a transient 
period of 10-15 seconds.This is followed by sympathetic nervous system 
activation,which releases adrenaline and noradrenaline which cardiac 
arrhythmias.Systolic blood pressure increases up to 30–40% of  baseline and 
heart rate increases by 20% of  baseline.The blood pressure and heart rate 
changes maximizes when increase in plasma adrenaline level increases 10 
fold and noradrenaline level increases 3 fold.This corresponds to the 1 minute 
of ECT.The plasma adrenaline level reaches the control level 10 minutes after 
ECT but noradrenaline level remained high even after 10 minutes of ECT.  
 Myocardial oxygen consumption will increase in ECT.It increases 
more in 1.Bilateral ECT,2.Elderly,3.During hyperventilation which causes 
hypocapnia Myocardial oxygen consumption increases during seizure activity 
and oxygen supply to myocardium will be reduced.So patients with 
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preexisting  disease have increase risk of Myocardial ischaemia and 
infarction.  
 Decrease in systolic and diastolic function of left ventricle may occur 
and remains up to six hours after Electroconvulsivetherapy.And also cardiac 
rupture can occur. 
Cerebral effects 
 Blood flow to the brain increases during ECT. This leads to increase in 
intracranial pressure.Cerebral oxygen consumption is also increases during 
ECT.Transient ischaemic attacks,intracerebral haemorrhage, and cortical 
blindness can also occur.Other complications include,prolonged seizures or 
status epilepticus.Cognitive side effects occurs commonly.Patients with pre-
existing dementia are more prone for cognitive side effects.Impairment of 
orientation, impaired attention, and memory loss are frequent problems after 
ECT. 
Continuation Electroconvulsive Therapy 
 Relapse of the psychiatric illness can be prevented by continuation 
ECT.After the first few months of ECT the risk of relapse is increased.so 
continuation of ECT is needed.Indications of continuation 
electroconvulsivetherapy includes patient’s preference,resistance and 
intolerance to the medicines, Pharmacotherapy resistant schizophrenia is 
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effectively treated with continuation ECT combined with neuroleptics.It can 
also prevents the relapse of schizophrenia after responding to the ECT. 
 A comparative study of effects of lithium and nortriptyline in 
combination with ECT was done in patients underwent continuation ECT.In 
that study both of the drugs given with ECT reduces the relapse when 
compared to the placebo.When lithium and nortriptylin was given combined 
with ECT it prevents the relapse more when compared to placebo.   
Maintenance Electroconvulsive Therapy 
 Recurrence of the psychiatry illness is prevented by the maintenance of  
ECT.Studies concluded that geriatric patients with unipolar  major depression 
undergoes maintenence ECT in addition with the administration of 
nortriptyline significantly increases the mean survival time than 
administration of nortryptyline alone.  
Pharmacological Therapy 
 Pharmacological treatment given to patients after ECT may vary with 
the clinical  diagnosis of the patient. Prophylactically  given medication after 
ECT is beneficial to the patients who are resistant to the pharmacological 
treatment and who have major depressive illness.Outcome of the patients 
after ECT depends upon the pre ECT condition.Remission rate is seen in 
patient who does not respond to the drug therapy and have chronic 
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psychiatric illness especially depression,but is not depends on age and 
physical illness.Melancholic features has no role in the prediction of response 
to ECT. 
Psychotherapy 
 Some patients may need psychotherapy after ECT.It is very useful in 
treating the residual symptoms and it encourages the patients to return to 
routine life.Efficacy of antidepressant action of ECT may be prolonged by 
cognitive behavioral therapy. 
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PHARMACOLOGY OF ESMOLOL 
 Esmolol hydrochloride is a cardio selective,competitive ultra short 
acting and intra venously acting beta blocker.It has faster onset of 
action.Esmolol has minimal partial agonistic activity or no direct effect on 
membrane potential at normal treatment doses.It blocks the stimulatory 
effects of norepinephrine on the sinus and AV node.It comes under 
classification of antiarrhythmic drugs,class II.Esmolol is rapidly eliminated 
from the plasma,with the elimination half life of 9-10 minutes. 
CHEMISTRY  
 Chemical formula of  Esmolol hydrochloride is (C16H25NO4.HCL) 
,(R,S)-4-[2 hydroxy-3-1[(1-methylethyl)amino]propoxy]benzenepropanoic 
acid methyl ester hydrochloride.and consists of following structure 
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 Molecular weight of Esmolol hydrochloride is 331.8.It has the pka 
value of 9.5.It poses the chiral centre and racemate is used clinically.Esmolol 
is a crystalline powder which is white to off-white in colour.It is very soluble 
in alcohol and freely soluble in water.It is available with octanol/water 
partition coefficient of 0.42.  
 Esmolol hydrochloride intended to provide a source of drug for use as 
a loading dose contains as a 100mg in 10 ml vial.It is prepared as a 
sterile,colorless,clear and a nonpyrogenic solution.To balance the ph from 4.5 
to 5.5 it is necessary to add Sodium Hydroxide or Hydrochloric Acid,1.688 
mg Sodium Acetate Anhydrous (equivalent to 2.8 mg Sodium Acetate 
Trihydrate) and 0.546 mg Glacial Acetic Acid. 
 Esmolol beta 1 adrenergic receptor blocker and is the most 
cardioselective agent with relatively little beta 2 blockade activity,at doses 
commonly used clinical settings.It is available only for intravenous infusion 
with the elimination half life of esmolol from the plasma is nearly 9.2 
minutes.It is best described by a two compartment open model.It blocks the 
beta 1 receptors present in the cardiac muscle at therapeutic doses and blocks 
the beta 2 receptors  present in the bronchial smooth muscles.  
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Pharmacokinetics and Metabolism 
 Plasma levels of  Esmolol can be determined by high performance 
liquid chromatography or gas chromatography-mass spectrometry.Esmolol 
not suitable for oral administration due to its rapid hydrolysis and is available 
only for intravenous use distribution is very rapid with an alpha phase half 
life of only two minutes.Esmolol is extensively and rapidly metabolized by 
erythrocyte cytosolic esterases to yield 3-[4-(2-hydroxy-3-{isopropylamino}-
propoxy)phenyl]propionic acid and methanol.These metabolite has very 
weak beta adrenergic blocking activity.Elimination half life of these 
metabolite is 4 hrs and it is cleared at glomerular filtration rate.Esmolol is not 
a substrate for erythrocyte membrane or plasma esterases.Less than 1% of 
Esmolol is excreated unchanged in urine.Esmolol Hydrochloride is cleared 
from the body at a rate of  285ml/kg/min,which is greater than cardiac 
output.Hepatic disease has no effect on,volume of distribution,total body 
clearance,elimination half life of esmolol.Pharmacokinetics of esmolol is not 
affected by renal failure,with the half life,volume of distribution and 
clearance are very similar in patients maintained on hemodialysis as in 
healthy individuals.Esmolol Hydrochloride is rapidly distributed in our 
body.Esmolol Hydrochloride is rapidly distributed within two minutes of 
administration.  
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 Methanol levels monitored in subjects getting Esmolol for 6 hrs at 
300microgram/kg/min ranged from 2.8 to 5.9 mg/lit and when administered 
for 24 hrs at 150mic/kg/min methanol level ranges from 2.9 to 13.2 mg/lit.In 
either case methanol level is less than two percentage of that normally 
associated with toxicity.55% of  Esmolol has been bound to human plasma 
protein, and has extensive presystemic metabolism. 
Pharmacodynamics 
 Esmolol given as an infusion of 50-200 mic/kg/min inhibits 
isoproterenol associated rise up in heart rate in healthy volunteers.Exercise 
induced tachycardia and hypertension were reduced by esmolol at a dose 
dependent manner over the range of 100-500 mic/kg/min with estimated 
EC50 values of 113 and 134mic/kg/min respectively.Single intravenous bolus 
dose of 100mg and above have been noted to prolong PR interval on ECG 
but not on QRS duration or the QT interval. More detailed 
electrophysiological studies in patient receiving 300mic/kg/min have shown 
no direct effect on intrinsic sinus automaticity, AV nodal refractoriness or his 
purkinjie system. negative inotropic effect have been observed at doses of 
16mg/min.,in patients with severe  left ventricular function. as suggested by 
its pharmacology. 
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  Esmolol is relatively bronchial sparing. for example ,esmolol 8-24 
mg/min given to cardiac patients with copd and chrnic obstructive pulmonary 
disease demonstrated large decreases in the heart rate (84± to 69± to beats 
/min.systolic blood pressure (124±3 to 106±3 mmhg)with out reducing 
fev1/fvc or PEFR.A mild asymptomttic decrease was recorded in 3 of 50 
patients studied. 
 When esmolol is administerded at a bolus followed by a continous 
infusion ,with a onset of b blockade activity occurs within two minutes with 
90% of steady state b blockade occurring within five minutes,The fall in 
plasma renin activity is gradual.Full recovery from the cardiac effects of 
esmolol is observed 18 to 30 minutes after terminating the infusion. 
THERAPEUTIC USE  
 1.To control the heart  rate in supraventricular tachycardia 
 2.Intra and post operative tachycardia and hypertension. 
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Mode of use  
 Esmolol injection is administered a continuous intravenous infusion  
using a controlled rate electric control pump.It is recommended that to reduce 
hyperosmolarity,esmolol be administered in a single entity soloution such as 
5%dextrose or normal saline.Dilution to a contration of 10g/l and 
administration into a large vein will help minimize phlebitis. 
 Esmolol is also available as a 100mg vial which intended to provide a 
premixed source of drug for use as a loading dose while the infusion is  being 
prepared. Single dose vial may also be appropriate for transient situations 
such as tracheal intubation,which only require a single,one time injection. 
INDICATIONS   
Supraventricular Tachycardia 
 Esmolol is used to control the ventricular rate rapidly in atrial 
fibrillation and atrial flutter.It is also in the setting of noncompensatory sinus 
tachycardia when it is deemed necessary to intervine.A placebo controlled 
trial of esmolol in patients with supraventricular tachyarrythmias 
demonstrated a 72% response rate,defined as a 20 bpm reduction in rate or a 
rate under100bpm.The average dose producing this response was 
97.4mic/kg/min. 
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 Esmolol has been used combined with digoxin in the acute treatment of 
atrial fibrillation and flutter.After a dose of 0.25 or 0.5 mg diogoxin,esmolol 
was administered in doses of 2mg/min.In another study  in patients with atrial 
flutter or fibrillation,esmolol was compared with verapamil.Both drugs were 
effective in controlling heart rate but a greater propotion reverted to sinus 
rhythm with esmolol,particularly when the onset of arrhythmia was recent. 
Intraoperative and postoperative tachycardia and/or hypertension 
 Postoperative hypertension is often a transient phenomena and is 
thought to be due to excessive catecholamine release.The patients frequently 
release exhibit tachycardia as well as hypertension.Beta blockade with 
esmolol is under investigation as an alternative to commonly used 
intravenous vasodilator therapy,typically the use of nitroprusside. 
 Tracheal intubation produces a hemodynamic response of hypertension 
of hypertension and tachycardia.This action is undesirable in patients with 
ischemic  heart disease and limited coronary blood flow reserve.The 
administration of a single bolus of esmolol prior to induction of anaesthesia is 
effective in attenuating this response. 
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Other uses 
 Other possible use under investigation include acute hypertensive 
crisis,acute myocardial ischemia,medical therapy for aortic 
dissection.management of thyrotoxicosis,induction of  bradycardia ,for 
performance of coronary bypass without the use of cardio pulmonary 
bypass,and treatment of the hyperdynamic effects of drug over dosage such 
as that of cocaine and theophylline. 
CONTRAINDICATIONS 
 Esmolol is contraindicated in patients with sinus bradycardia, 
cardiogenic shock, heart block greater than first degree,or overt heart failure. 
CAUTION 
Hypotension: 
  Hypotension is defined as systolic pressure less than 90 mmHg and/or 
diastolic pressure less than 50 mmHg.In clinical studies 20-50% of patients 
treated with esmolol have experienced hypotension.About twelve percentage 
of the patients had symptoms mainly diaphoresis and dizziness. Patients with 
low BP should be closely monitored. To reverse the hypotension, decrease 
the dose or termination of infusion,usually it will take 30 minutes. 
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Congestive heart Failure 
 The decrease in contractility with beta blocker therapy can cause an 
exacerbation of congestive heart failure.This is especially true of acute heart 
failure.In chronic heart failure states,β-blockers are better tolerated,at least in 
small doses. 
Sinus bradycardia 
 Esmolol may lead to exacerbation of pre-existing sinus bradycardia 
with resultant hemodynamic compromise. 
Heart block greater than first degree 
 In the presence of second degree heart block,AV nodal conduction can 
be further compromised.It could potentially lead to a higher degree of heart 
block and worsening bradycardia with more serious hemodynamic 
disturbances. 
Cardiogenic shock 
 Esmolol,as is the case with any beta blocker,has a negative ionotropic 
effect by decreasing the endogenous beta adrenergic stimulation of cadiac 
contractility.In a patient with a low cardiac output this may cause,or 
worsen,cardiogenic shock. 
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ADVERSE EFFECTS 
Potentially life threatening effects 
 Sudden death has been reported following use of esmolol.Esmolol may 
cause profund bradycardia and hypertension in patients with severe 
impairment of myocardial function who are dependent on sympathetic drive 
to maintain their cardiac output.Esmolol should be discontinued at the first 
sign of deteriorating myocardial function.Although esmolol is short 
acting,immediate intervention may require dopamine or 
dobutamine.Verapamil administered concurrently with esmolol has resulted 
in cardiac arrest. 
Acute overdose 
 Accidental overdosage of esmolol has generally occurred as an error in 
dilution.Known doses of 5000 to 6000mic/kg being administered over 1-2 
minutes have been reported.Toxic effects are bradycardia, 
hypotension,drowsiness and loss of consciousness.These effects generally 
resolves within 10 minutes of stopping the infusion,although in some cases 
pressor agent was given.Bradycardia could not be treated with 
atropine.Bronchospasm may respond to a beta2 stimulating agent.Cardiac 
failure may respond to administration of glucagon.Cardogenic shock may 
require the administration of dopamine or dobutamine initially high doses. 
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 Symptomatic hypotension will usually respond to the administration of 
fluids and/or pressure agents,although the majority of cases of hypotension 
are asymptomatic and require no therapy apart from reduction in esmolol 
usage. 
Severe irreversible adverse effects 
 Hypotension is the most common side effected with esmolol.No other 
serious or irreversible side effects have been described. 
Symptomatic adverse effects 
 Symptomatic adverse effects include hypotension, bradycardia, 
dizziness, diaphoresis, other CNS side effects include weakness and 
irritability and intravenous site inflammation.Approximately 1% of patients 
had peripheral ischemia. 
Interferance with clinical pathology tests 
 There is no reports of esmolol affecting the results of any blood tests. 
High risk groups 
 No information is available on the use of esmolol in neonates. 
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Breast milk 
 No information available regarding the passage of esmolol or its 
metabolites through breast milk. 
Pregnant women 
 Administration of esmolol in pregnant women can lead to dose related 
beta blockade of the fetus as well as a decrease in fetal arterial po2.Fetal 
bradycardia has been repoted when a mother was treated with esmolol to 
reduce blood pressure in the face of an intracranial arterial venous 
malformation.Based upon this esmolol should not be used in pregnancy. 
Children 
 One study was performed in children aged 2-16 yrs suggests that the 
dosage needed to cause the beta blockade is larger than in adults.The study 
recommended a dose of 600mic/kg infused over 2 min followed by infusion 
200mic/kg/min.However controlled trials have not been performed in this 
population.Therefore true risk/benefit cannot be assessed. 
The elderly 
  No information is available regarding the safety and efficacy of 
esmolol in the elderly. 
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CONCURRENT DISEASE 
Heart disease 
 Patients with AV heart block other than first degree heart 
block,cardiogenic shock,bradycardia or cardiac failure should not receive 
esmolol. 
Chronic obstructive pulmonary disease or asthma 
 Patients with these diseases should be closely monitored during the 
administration of esmolol. 
Diabetes 
 Esmolol should be used with caution in patients with diabetes since 
beta blockade may mask the symptoms of hypoglycemia. 
Renal disease 
 In renal failure the metabolite AS-8123 may accumulate with the 
potential for causing undesirable bradycardia and hypotension. 
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DRUG INTERACTIONS 
Potentially hazardous interactions 
Verapamil 
 It has a marked cardiac depression properties as well the potiential for 
supreesion of AV conduction.Use esmolol,which has similar effects,has 
situated in cardiac arrest in patients who have received both medications 
simultaneously. 
Digoxin 
 Esmolol when concurrently administered with digoxin under steady 
state conditions,caused a 10% increase in digoxin levels in healthy 
males.This increase in serum digoxin levels are not associated with an 
increase in PR interval or with significant changes in heart rate and blood 
pressure. 
Warfarin 
 When esmolol and warfarin are administered concurrently,there are no 
changes in the plasma warfarin concentration.However there is an increase in 
serum levels of esmolol.These changes are small does not result in marked 
hamodynamic changes. 
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Morphine 
 Morphine has been noted to cause an increase in steady state blood 
levels of esmolol when administered concurrently. 
Succinylcholine 
 Succinylcholine has been shown to cause an increase in neuromuscular 
blockade in patients receiving esmolol.   
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PHARMACOLOGY OF LABETALOL 
 Labetalol hydrochloride is a competitive antagonist at beta 1 and beta 2 
adrenoreceptors.,with some intrinsic activity at beta 2 receptor.Labetalol in 
addition to beta adrenoreceptor blocking property has competitive alpha 
receptor antagonistic properties at post synaptic region.Labetalol designed as 
5-{(r,s)-1-hydroxy-2-{(1-methyl-3-phenylpropyl)aminoethyl}-salicylamide 
hydrochloride and it contains following structure: 
 
 Molecular formulae of labetalol is C19 H24 N 2O3. HCl and it has 
molecular weight of 364.9.It consists of  two optical centers and so clinical 
preparation consists of equal proportion of four isomers.Dilevalol, the R,R' 
stereoisomer, makes up 25% of racemic labetalol.It is a crystalline powder 
which is white or off white in colour.Labetalol is odorless and it is soluble in 
water. 
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 Labetalol hydrochloride injection is a clear, sterile colorless to light 
yellow, isotonic aqueous solution for intravenous (IV) injection with a pH 
range of 3.0 to 4.5. ,containing labetalol hydrochloride 5 mg /ml in 20 ml or 
40 ml vials.excipients include dextrose,methylparaben,and 
propylparaben.The injection is intended for slow intra venous injection or 
suitably diluted intra venous infusion. 
CLINICAL PHARMACOLOGY 
 Competitive beta adrenergic blockade has been demonstrated in 
humans by parallel shift in the log dose-heart rate response curve for 
isoproterenol. Competetive alpha adrenergic blockade has been demonstrated 
in humans by the parallel shift in the log –dose pressor respone curve to 
phenylephrine. 
Pharmacodynamics 
 The potency ratio of alpha:beta adrenoreceptor antagonism is 
approximately 1:7 when given intravenously and 1:3 when given orally.After 
administering the  intravenous dose of 0.5 to 2.0mg /kg ,labetalol may 
produce an immediate fall in blood pressure associated reduction in the heart 
rate.Cardiac output may not be affected much.Peripheral vascular resistance 
may be reduced.Labetalol is very useful in blunting heart rate and blood 
pressure response to exercise.It also blocks the pressor and heart rate 
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response to parentral epinephrine.Isoproterenol induced fall in diastolic blood 
pressure.Orally administered Labetalol decreases the blood pressure as well 
as heart rate.Single oral dose of  labetalol given to patients with ischemic 
heart disease has no significant effect on intraventricular conduction, sinus 
rate, or QRS duration.It prolongs the atrioventricular (A-V) conduction time 
and effective refractory period.  
 The effects on A-V nodal refractoriness were inconsistent.Through a 
mixture of its alpha- and beta-blocking effect,it can produce dose related fall 
in blood pressure with out causing tachycardia or bradycardia.Elevated 
plasma renins are reduced.Doses of labetalol  that controlled hypertension 
may not affect renal function in mildly to severely hypertensive patients with 
normal renal function.Blood pressure is lowered more in the standing person 
than in the supine person due to alpha receptor blockade with symptoms of 
postural hypotension. 
Pharmacokinetics and Metabolism 
  Labetalol is  absorbed rapidly after oral administration(well absorbed 
orally).In fasting individuals the peak plasma concentration occurred 20-60 
minutes after a dose of 100mg where as 40-90 minutes after a dose of 200 
mg.Systemic bioavailability ranged from 11-86% after a dose of 100 mg.The 
wide variation among individuals in total labetalol plasma concentration is 
due to extensive pre systemic metabolism(14-89%) plasma half life range 
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from 1.7-6.1 hr with a mean of 3.3 hr.Plasma protein binding capacity of 
Labetalol is 50%.Labetalol undergoes hepatic biotransformation,and less than 
5% of the drug is recoverd unchanged in the urine.The bioavailability 
considerably incresed in hepatic cirrhosis.Volume of distribution in humans 
is 3.4-10.7l/kg/l.Less than 5 percentage of labetalol is excreted unchanged in 
urine.  
 Metabolites of labetalol are mainly excreted in urine but 12-27% 
excreted in feces.Smaller amounts of o-phenyl glucoronide has been 
identified. 
INDICATIONS AND USAGE 
 Inj.Labetalol is mainly used in hypertension,angina pectoris,where a 
hypotensive technique is indicated in anaesthesia,and pheochromocytoma. 
 DOSAGE AND ADMINISTRATION 
 Inj.Labetalol hydrochloride is mainly used intravenously in 
emergencies where rapid control of BP is needed,because the intravenous 
route avoids presystemic metabolism the dose should be proportionately 
lower than oral dosage.It is administered either by repeated intravenous 
injection or slow intravenous injection. 
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Repeated Intravenous Injection: 
 Inj.Labetalol hydrochloride can be given  for the intravenous treatment 
of severe hypertension ,with an starting dose of 20 mg administered over one 
to two minutes :additional doses of 40 mg and 80 mg at 10 minutes time 
interval until a satisfactory response has been obtained or a total of 300 mg 
has been administered.heamodynamic  response usually occur within five 
minutes. 
Slow Continuous Infusion 
 Alternative to repeated intravenous infusion ,slow continuous infusion 
at at rate of a starting dose 2mg/min and continued until satisfactory response 
has been obtained.Effective dosages range from 50-300 mg.for hypertensions 
of pregnancy and for hypertensions after acute myocardial infarction;for the 
former an initial rate of 20mg/hr doubled every 30 minute until a satisfactory 
response has been obtained.In the latter ,an initial dose of 15 mg/hr gradually 
increased until a satisfactory response has been observed. 
CONTRAINDICATIONS 
 Labetalol is absolutely contraindicated in bronchospasm,untreated 
heart failure,low cardiac output status,bradycardia,severe hemorrhage and 
hypoglycemia. 
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CONDITIONS TO BE USED WITH CAUTION  
 Severe hepatocellular injury may rarely occur with Labetalol 
therapy.Usually it is reversible,and even hepatic necrosis and death may 
occur.Patients on Labetalol should undergo periodic hepatic laboratory 
tests.Laboratory testing should be done at the very first symptom or sign of 
liver dysfunction like persistent anorexia, pruritus, unexplained “flu like” 
symptoms, jaundice, right upper quadrant tenderness dark urine and 
jaundice.If there is evidence of liver injury or jaundice, labetalol should be 
stopped and not restarted. 
Heart Failure 
 The adverse effects of beta adrenoreceptor blockade on myocardial 
contractility are counteracted by the alpha adreno blocking action of labetalol 
which causes a reduction in after load.labetalol causes a reduction in 
myocardial contractility and in patients with impared left ventricular function 
,may cause a reduction in cardiac output. 
In Patients without a History of Cardiac Failure 
 Labetalol has a variable effect on the heart rate and can depress the 
conduction in A-V node. In patients with high grade atrioventricular block or 
sever sinus bradycardia its use may be hazardous. 
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Ischemic Heart Disease 
 Labetalol dosage shold be tappered slowly mainly in patients with 
coronary artey disease, in order to avoid exacerbations of angina pectoris and 
myocardial infarction.In such situations,labetalol should be readministered 
absolutely,for a period of time and further measures for managing unstable 
angina should be taken. 
Nonallergic Bronchospasm (e.g., Chronic Bronchitis and Emphys ema) 
 Labetalol has got a lesser tendency to cause bronchoconstriction than 
propranolol but has been reported to cause severe bronchospasm in patients 
with asthma.It may render such patients unresponsive to normal doses of  
bronchodilators such as albuterol. 
Pheochromocytoma 
 Labetalol inhibits both the chronotropic and pressor effects of 
circulating catecholamines.It has been found to be effective both pre and 
perioperatively in the management of patients with pheochromocytoma 
.Satisfactory blood pressure control was reported in patients having adrenal 
tumors provided with labetalol.However some patients could not tolerate 
high dose of labetalol and was treated with a combination of propranolol and 
phenoxybenzamine. 
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Diabetes Mellitus and Hypoglycemia 
 The metabolic response to hypoglycemia is achieved,in part through 
stimulation of beta-adrenoreceptors.Thus labetalol may enhance any tendency 
to hypoglycemia and will mask some of the symptomatic responses such as 
tremor. 
Major Surgery 
 Discontinuing long term treatment of  beta blocker therapy prior to 
surgery should be avoided. 
PRECAUTIONS 
 Intraoperative Floppy Iris Syndrome (IFIS) which is recorded while 
doing cataract surgery in some patients getting treatment with alpha -1 
blocker.This is a type of small pupil syndrome which  has combined flaccid 
iris that shows no good response during intraoperative irrigation 
currents,inspite of preoperative standard application of mydriatic drugs,there 
is an increase in intraoperative miosis and effective prolapse of the iris 
directed on the side of phacoemulsification incisions.Ophthalmologist 
mandatorily should be aware and be ready for modification of surgical 
techniques like way of using iris hooks,viscoelastic substances or iris 
dilators.No marked beneficial effects recorded ,stopping alpha one blocker 
therapy before cataract surgery. 
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After Coronary Artery Bypass Surgery: 
 Patient group having low cardiac indices and increased systemic 
vascular resistance following intravenous Labetalol noted to have significant 
reduction in cardiac output and very smaller  change in systemic vascular 
resistance.These patients are more prone for hypotension following labetalol 
treatment.So labetalol is not recommended in that patients. 
Drug Interactions 
 Potentially hazardous interaction .The heart rate may fall during 
general anaesthesia in patients treated with labetalol.The hypotensive effect 
of halothane enhanced by labetalol.Care should be taken if labetalol is used 
concomitantly with drugs like verapamil.The bioavailability of labetalol can 
be increased by concurrent administration of cimetidine.It has been suggested 
that there may be an increased incidence of tremor during therapy with a 
combination of labetalol and tricyclic antidepressants. The bioavailability of 
labetalol is increased when it is administered with food. 
Pregnancy 
Teratogenic Effects - Pregnancy Category C 
 Although no tertogenic effects have been demonstrated ,the routine use 
of labetalol during first trimester is not recommended. 
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Nonteratogenic Effects 
 Labetalol crosses placenta and adverse effect on fetus is 
possible.however in practice bradycardia,hypotension,and hypoglycemia are 
uncommon. 
Nursing Mothers 
 Labetalol excreted in breast milk with an average milk to plasma ratio 
of 1.5.however the small amount of drug ingested by the nursing infant 
prouduce any adverse effects. 
ADVERSE REACTIONS: 
 Acute over dosage may result in bradycardia and cardiogenic 
shock.Labetalol may cause postural hypotension,precipitate heart failure,it 
has been reported to cause bronchospasm,licheniform skin rashes,retention of 
urine,systemic lupus erythamatosus.Distrurbances of liver function including 
frank jaundice and liver necrosis have also been recorded.Labetalol in 
generally well tolerated but may cause headache,nasal stuffiness,scalp 
tingling ejaculatory failure,and worsening of intermittent claudication.Other 
unwanted effects include dyspepsia,nausea,vomiting and night mare. 
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MATERIALS AND METHODS 
 This was a prospective randomized controlled double blinded 
study.After ethical committee approval and informed written consent 
obtained from the family members of the patients,the study was conducted in 
90 eligible patients after explaining the procedure details to family members 
of the patients.This study was conducted at Government Rajaji Hospital 
attached to Madurai Medical College. 
 
INCLUSION CRITERIA :  
 1.Psychiatric patients undergoing Electro 
convulsive therapy 
 2.ASA I and II patient 
                                              3.Either sex 
                                              4.Age between18-60 years 
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EXCLUSION CRITERIA     : 
        1. Patients with II degree AV conduction   
       block or greater, 
                                             2. Bradycardia Heart rate less than 50/min  
                                             3. Systolic Blood pressure less than 90mmhg 
                                             4. Asthmatic patients  
                                             5. patients with history of drug allergy 
                                             6. Recent Myocardial infarction 
               (with in 3 months) 
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METHODOLOGY 
 90 ASA I and II  patients undergoing Electro convulsive therapy were 
randomly divided into three groups.Each group contains thirty patients. 
Patient was premedicated with Inj.Glycopyrrolate 0.2 mg im 30 minutes 
before ECT.Patient shifted to ECT room and IV line secured with wide bore 
IV cannula. 
 Group C-Control group received normal saline 5ml, 
 Group E-Esmolol group received 1mg/kg of esmolol, 
 Group L-Labetalol group received 0.25mg/kg of labetalol. 
PREOPERATIVE EVALUATION  
  A routine pre anaesthetic assessment of the patient included  history 
regarding the severity and duration of symptoms, history of any other 
systemic illness, history of any other previous surgeries. A detailed 
examination was done by assessing the general condition, airway , nutritional 
status, weight and height of the patient. A thorough systemic examination of 
cardiovascular and respiratory system was made.  The following basic 
investigations like haemoglobin, urine examination for sugar ,albumin and 
microscopy, blood sugar, blood urea, serum creatinine, standard 12 lead 
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ECG, echocardiography, serum electrolytes and X ray chest were done for all 
patients.  
 MONITORS: 
 Pulse oxymetry,Blood pressure cuff,ECG leads,Capnography was 
attached 
MONITORING OF BASELINE PARAMETERS: 
 Baseline Pulse rate,Systolic and Diastolic Blood pressure,SPO2 were 
recorded and marked as “o” 
PROCEDURE: 
 Patient was preoxygenated with 100% Oxygen and patient was induced 
with Inj.Propofol 1-2 mg/kg.Immediately after induction patients in control 
group received normal saline 5ml,and group E and L received Inj.Esmolol 1 
mg/kg and Inj.Labetalol 0.25 mg/kg respectively as bolus.Parameters 
monitored and to be recorded after 1 min of test drug and noted as X.After 
that BP cuff was inflated above the systolic BP to isolate the another limb 
then Inj.Succinylcholine 1mg/kg was given. ECT current was given after two 
minutes of administration of test drug after  applying an oral soft bite 
block.Electric shock current applied to the patients were same. 
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 In Government Rajaji Hospital ECT electrodes were placed 
bitemporally.A Monitored Electroconvulsive Therapy Apparatus (MECTA) 
was used to deliver the electrical stimulus.Assesement of the effectiveness of 
the electric current applied in ECT was made by seeing the tonic-clonic 
seizures in the isolated arm.Patient was ventilated with 100% oxygen by 
controlled and assisted method until spontaneous respiration 
returned.Baseline pulse rate,systolic BP and diastolic BP were recorded and 
marked as “o”.After 1 minute of administration of test drug these parameters 
monitored and recorded as “X”.After 1 minute,3 minutes,5 minutes and 10 
minutes of ECT pulse rate,systolic BP and diastolic BP were recorded and 
marked as A,B,C,D accordingly. Fall in blood pressure more than 25% from 
baseline was considered as hypotension and treated IV fluids and fall in pulse 
rate less than 50/min was considered as bradycardia and treated with 
Inj.Atropine 0.3 mg.By using the statistical analysis system all statistical 
analysis was done.The relation among the treatments was determined by T 
test. P value <0.05 is statistically significant. 
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STATISTICAL ANALYSIS 
 The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of computer 
using Epidemiological Information Package (EPI 2010) developed by 
Centre for Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square ‘t’ value and   'p'  values were calculated.  ‘t’  test was 
used to test the significance of difference between quantitative variables and  
Yate’s and Fisher’s chi square tests for qualitative variables. A 'p' value less 
than 0.05 is taken to denote significant relationship 
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 OBSERVATIONS AND RESULTS 
                Group C :Control cases – 30 cases 
                Group E : Patients given IV Esmolol – 30 cases 
               Group L :Patients given IV Labetalol – 30 cases 
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A : PROFILE OF CASES STUDIED  
A : Age Distribution 
Group 
Age in years 
Mean SD 
Control Group 35.2 8.0 
Esmolol Group 31.5 9.2 
Labetolol Group 33.5 8.0 
‘p’ value between 
Control & Esmolol 
Group 
0.1078 
Control & Labetolol 
Group 
0.4317 
Esmolol & Labetolol 
Group 
0.374 
 
Mean age of group C was 35.2 years and group E was 31.5 years & Mean 
age of group L was 33.5 years.There is no statistical difference 
between these groups. 
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This is the graphical representation of  mean age of all the three group.There 
is no significant difference in all three groups 
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Table A2 : Sex Distribution 
Group 
Sex 
Male Female 
No % No % 
Control Group 17 56.7 13 43.3 
Esmolol Group 14 46.7 16 53.3 
Labetolol Group 13 43.3 17 56.7 
‘p’ value between 
Control & Esmolol Group 0.3029 
Control & Labetolol Group 0.2195 
Esmolol & Labetolol Group 0.5 
 
56.7% in Group C and 46.7% in Group E &43.3% in group L were male. 
43.3% in Group C& 53.3 in Group E & 56.7 % in group L were female. The 
sex distribution did not have any statistical significance. 
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This graphs shows the sex distribution in all the three groups.This is not 
statistically significant. 
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Table A3 : ASA 
Group 
ASA 
I II 
No % No % 
Control Group 24 80 6 20 
Esmolol Group 26 86.7 4 13.3 
Labetalol Group 22 73.3 8 26.7 
‘p’ value between 
Control & Esmolol Group 0.3653 
Control & Labetolol 
Group 
0.1667 
Esmolol & Labetolol 
Group 
0.3805 
 
80%  in group C & 86.7% in group E & 73.3% in group L comes under ASA 
I.20% in group C &13.3 & 26.7 group L comes under ASA II.ASA grading 
didnot show any statistical difference.  
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This graph shows the ASA of all the three groups.This is not statistically 
significant. 
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Table A4: Height / Weight / BMI 
Group 
Height (cms) Weight (kgs) BMI 
Mean SD Mean SD Mean SD 
Control Group 158.2 8.4 57.7 6.8 23.1 2.9 
Esmolol Group 156.9 2.3 55.3 7.8 22.5 3.2 
Labetalol Group 155.2 6.8 56.2 7.2 23.4 3.2 
‘p’ value between 
Control & Esmolol Group 0.0816 0.2077 0.4537 
Control & Labetolol 
Group 
0.0705 0.4112 0.7193 
Esmolol & Labetolol 
Group 
0.3737 0.6444 0.2952 
 
Mean BMI of C was 23.1 and Group E was 22.5 and group L was 23.4. 
The mean BMI of these groups were not statistically significant . 
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This is the graphical representation of the BMI of three groups.This is not 
statistically significant. 
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Table B4 : Changes in  SPO2 
Group 
SPO2 
mean SD 
Control Group 99.1 0.6 
Esmolol Group 99.1 0.6 
Labetalol Group 99.1 0.6 
‘p’ value between 
Control & Esmolol Group 1.0 
Control & Labetolol Group 1.0 
Control Group 1.0 
 
\ 
SPO2 of group C,group E,group L is 99.1.SPO2 is not statistically 
significant. 
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This the graphical representation of SPO2 of three groups.There is no 
significance. 
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B: EFFICACY OF THE THREE DRUGS 
Table B1: Changes in Pulse Rate 
Pulse 
Rate at 
Pulse Rate of ‘p’ Value between 
Control 
Group 
Esmolol 
Group 
Labetolol 
Group 
Control 
& 
Esmolol 
groups 
Control 
& 
Labetolol 
groups 
Esmolol & 
Labetolol 
Groups 
Mean SD Mean SD Mean SD 
P R – 0 101.1 3.1 100.7 3.1 99.1 3.8 0.28 0.1054 0.0693 
P R – X 111.1 3.1 90.7 3.3 108.5 7.3 <0.0001 0.0716 0.0001 
P R – A 125.2 5.9 98.3 2.5 125.0 4.1 <0.0001 0.8801 <0.0001 
P R – B 137.5 3.1 100.5 3.0 136 2.5 <0.0001 0.3181 <0.0001 
P R – C 108.1 2.8 109.0 5.5 91.1 3.1 0.4443 <0.0001 <0.0001 
P R – D 111.4 5.6 109.9 4.0 92.1 3.3 0.2251 <0.0001 
<0.0001 
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CHANGES IN PULSE RATE
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This graph shows the changes in heart rate during ECT in all groups 
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Table B2: Changes in Systolic Blood Pressure 
Systolic 
Blood 
Pressure 
at 
Systolic Blood Pressure of ‘p’ Value between 
Control 
Group 
Esmolol 
Group 
Labetolol 
Group 
Control 
& 
Esmolol 
groups 
Control 
& 
Labetolol 
groups 
Esmolol 
& 
Labetolol 
Groups 
Mean SD Mean SD Mean SD 
SBP – 0 131.6 8.2 131.7 8.2 131.3 8.4 0.9501 0.8774 0.8288 
SBP – X 110.6 7.0 109.7 7.0 109.1 5.2 0.608 0.3635 0.7384 
SBP – A 152.5 7.6 121.5 4.3 150.3 5.0 <0.0001 0.1898 <0.0001 
SBP – B 137.6 8.4 119.5 4.5 124.1 8.8 <0.0001 <0.0001 0.0134 
SBP – C 138.3 8.9 135.4 7.3 111.6 5.5 0.1781 <0.0001 <0.0001 
SBP – D 131.9 6.6 132.2 6.5 112.3 7.2 0.8756 <0.0001 <0.0001 
 
This table shows the Systolic BP at various time during ECT in all the 
three groups. 
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CHANGES IN SYSTOLIC BLOOD PRESSURE
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This graph shows the changes of  systolic bp at various time in all three 
groups 
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Table B3: Changes in Diastolic B.P. 
Diastolic 
B.P.at 
Diastolic B.P. of ‘p’ Value between 
Control 
Group 
Esmolol 
Group 
Labetolol 
Group 
Control 
& 
Esmolol 
groups 
Control 
& 
Labetolol 
groups 
Esmolol 
& 
Labetolol 
Groups 
Mean SD Mean SD Mean SD 
DBP – 0 81.2 5.3 81.5 5.1 81.5 5.5 0.8438 0.8114 0.9614 
DBP – X 84.1 5.3 72.1 4.4 82.5 3.3 <0.0001 0.1666 <0.0001 
DBP – A 91.5 5.6 81.1 5.1 91.8 6.0 <0.0001 0.8588 <0.0001 
DBP – B 93.1 5.8 82.1 5.0 80.5 5.7 <0.0001 <0.0001 0.2337 
DBP – C 86.0 3.6 83.4 6.0 74.1 5.8 0.1961 <0.0001 <0.0001 
DBP – D 85.1 5.3 86.5 4.0 73.7 6.3 0.2325 <0.0001 <0.0001 
 
This table shows the recorded values of Diastolic BP during ECT in all three 
groups. 
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CHANGES IN DIASTOLIC BLOOD PRESSURE
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This Graph shows the Diastolic Blood Pressure change in all three groups. 
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REVIEW OF LITERATURE 
 1. Castelli I& Steiner in 1995 studied the comparative effects of Esmolol 
and Labetalol in attenuation of hemodynamic responses after ECT.In that 
study they studied 18 patients with atleast one cardiac risk factor.They 
compared the effects of five types of pretreatment.The patient did not receive 
any drug in the first session of ECT.Then the patient received Esmolol 
1.3mg/kg and 4.4mg/kg,Labetalol 0.13mg/kg and 0.44mg/kg in subsequent 
sessions.They found that hemodynamic responses (rise in heart rate,systolic 
bp,diastolic bp) occurs 1 minute after ECT.They concluded that 
hemodynamic responses were attenuated (50% reduction in HR &BP) by 
Esmolol 1.3mg/kg and Labetalol 0.13mg/kg.These responses are almost 
eliminated at the doses of Esmolol 4.4mg/kg and Labetalol 0.44mg/kg. Even 
after 10 minutes of ECT systolic BP was low after Labetalol treatment but 
not so after Esmolol. 
 2. Howie et al defined the dose range of Esmolol in attenuation of 
hemodynamic responses after ECT.They divided 20 patients into placebo 
group and Esmolol group.Esmolol group received Esmolol 500mic/kg/minute 
followed by Esmolol 300mic/kg/minute (high dose) or 200mic/kg/minute 
(medium dose) or 100mic/kg/minute (low dose) infusion during ECT.  
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each patient given either placebo or Esmolol 500mic/kg/minute bolous 
followed by high or medium or low dose infusion.The infusion or placebo 
stopped 3 minutes after ECT.They found that mean heart rate was decreased 
significantly from 3-7 minutes.The decrease in heart rate was high 
dose>medium dose>low dose infusion.They concluded that Esmolol bolus 
dose of 500mic/kg/minute followed by 300mic/kg/minute of infusion reduces 
heart rate maximum when compared to medium or high dose of infusion.    
     3.Avramom MN et al studied the efficacy of IV nicardipine in 
attenuating hemodynamic responses after ECT when used alone or combined 
with Labetalol.Patient underwent series of studies.Patient received either 
placebo or IV nicardipine by rapid infusion(1, 2.5, 5, 10, and 15 mg) or bolus 
injection (1.25, 2.5, and 5 mg), either alone or in combination with Labetalol 
10mg IV.At 1- to 5-minute intervals heart rate (HR) and Mean arterial 
pressure (MAP) were recorded. When nicardipine 5 mg i.v.given as rapid 
infusion decreases the MAP significantly.If they increases the nicardipine 
dosages of 10 to 15 mg i.v. did not decrease the MAP greater than 5mg bolus 
dose of iv nicardipine.The heart rate increased when MAP decreased after 
giving the bolus dose of 5mg nicardipine. The hemodynamic responses after 
ECT was attenuated effectively by  nicardipine 2.5 to 5 mg i.v. bolus, in 
combination with labetalol 10 mg i.v.Nicardipine does not significantly affect 
the seizure duration. 
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 They concluded that  hemodynamic responses after ECT was 
significantly affected by Nicardipine 2.5 mg i.v. bolus in combination with 
labetalol 10 mg i.v.It was found that this combination reduces the mean 
arterial pressure 20% before ECT and at the time of discharge. 
        4.Kovac et al compared placebo with 2 doses of  Esmolol in attenuation 
of hemodynamic responses after ECT.Patient received either placebo or 
Esmolol 100mg or 200 mg as bolus.Both the doses of Esmolol reduces 
hemodynamic responses after ECT significantly when compared to placebo.It 
was found that Esmolol bolus dose of 100 mg significantly reduces heart rate 
and mean arterial pressure up to 4 minutes after ECT where as bolus dose of 
200mg reduces heart rate and mean arterial pressure up to 18 minutes after 
ECT.But Esmolol bolus dose of 200mg shorten the duration of seizures.So 
low dose of Esmolol  found to be effective without altering the seizure 
duration. 
      5.Sarvesh P singh et al studied the effects of Esmolol and Labetalol in 
attenuation of sympathetic response to laryngoscopy and intubation.They 
divided the patients into 3 groups(control group received saline,esmolol 
group received 0.5mg/kg esmolol and labetalol group received 0.25mg of 
labetalol)Test drugs were given 2 minutes before laryngoscopy.Heart 
rate,Systolic BP and Diastoloc BP were measured prior to intubation and 
after 1,3,5,10 of intubation. 
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 Both the drugs in low dose raduces sympathetic responses.They 
concluded that labetalol 0.25mg/kg is the better agent in reducing the 
sympathomimetic responses during laryngoscopy and intubation. 
      6. Jung Hee Ryu et al compared the effects of IV Labetalol 0.4 mg/kg and 
IV Nicardipine 20 mic/kg to attenuate the hemodynamic responses during 
laryngoscopy and endotracheal intubation.Both the drugs were given 4 
minutes before intubation.120  patients were divided into four  groups.40 
patients received 0.4 mg/kg of labetalol  or 20 mic/kg of nicardipine (40 
patients)  before intubation in part I.In part II to receive 0.4 mg/kg of 
labetalol( 40 patients) or 20 mic/kg of nicardipine (40 patients) after 
intubation if hypertension occurred.The amount of additional drug needed to 
reduce the hemodynamic responses wera noted. In part I and part II patients 
who had taken nicardipine required additional dose of drug less likely when 
compared to labetalol.But labetalol reduces the incidence of tachycardia 
when compared with nicardipine during intubation.SO they concluded that 
labetalol reduces the hemodynamic responses significantly without increasing 
the heart rate when compared to nicardipine. 
      7. Mulgaokar G D et al assesed the cardiac function changes in patients 
undergoing ECT.80 psychiatric patients underwent ECT was included in that 
study.ECT resulted in increased blood pressure and rate pressure product and 
also shortening of preejection period.  
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 Cardiac contractility and myocardial oxygen demand was increased as 
a result of changes in rate pressure product and shortening of  pre ejection 
period.These effects were mainly due to catecholamines such as epinephrine 
and norephinephrine released during ECT. 
       8.Mohammad umar zhoor et al studied the use of lidocaine and 
nitroglycerine in attenuation of stress response during ECT.Patients were 
allocated into 3 groups. Group A is control group,group B received lidocaine 
1mg/kg and group c received nitroglycerine 3 mic/kg after induction.Heart 
rate,MAP was 2 minutes of administration of test drug and 1min after 
ECT.65% patients showed significant reduction of  HR and MAP in group B 
compared to group A.52% showed significant reduction of  HR and MAP in 
group C compared to group A.It was concluded that NTG provided more 
hemodynamic stability in post-ECT period as compared to lignocaine which 
only prevented a surge in HR without any effect on MAP.It was concluded 
that NTG can safely be instituted for anaesthesia in ECT patients for 
prevention of hemodynamic stress response.  
      9. D O’Flaherty et al compared the haemodynamic responses in 82 
patients underwent electroconvulsive treatments were randomly assigned to 
receive either nitroglycerin 3 micrograms.kg-1, esmolol 2 mg.kg-1 or 
placebo. These drugs were given shortly after the suxamethonium and 2 min 
before the electroconvulsive therapy in all cases.  
95 
 
 Heart rate was significantly lower with esmolol 1 min after therapy as 
was blood pressure (systolic and diastolic). The pulse rate was higher 
following nitroglycerin than placebo, which in turn was higher than esmolol. 
The three groups did not differ with regard to seizure duration. The results 
demonstrate that esmolol is more effective than nitroglycerin in controlling 
the haemodynamic response to electroconvulsive therapy. With recent 
emphasis on stabilisation of heart rate in preference to blood pressure in at-
risk cardiac patients, our study suggests that, in the doses selected, esmolol is 
preferred to nitroglycerin to control the heart rate response to 
electroconvulsive therapy. 
MB Weinger at al studied the cardiovascular effects of ECT after pre-
treatment of 10 patients with esmolol (1.0 mg/kg), fentanyl (1.5 
micrograms/kg), labetalol (0.3 mg/kg), lidocaine (1.0 mg/kg), and saline 
solution (control), using a double-blind, randomized block-design. Each 
patient received all five pretreatment regimens over the course of five ECT 
sessions. During control studies, arterial blood pressure and heart rate 
increased significantly in all patients after ECT (P less than 0.05 and P less 
than 0.01, respectively). The rate-pressure product increased by an average of 
336% +/- 14% (P less than 0.01).  
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 There were appreciable individual differences in the cardiovascular 
response to ECT, independent of pretreatment (P less than 0.01). 
Pretreatment with esmolol and labetalol significantly reduced the 
hemodynamic response to ECT, compared with fentanyl, lidocaine, or saline 
solution (P less than 0.05). Esmolol attenuated arterial blood pressure to a 
larger extent than did labetalol (P less than 0.05). Compared with saline 
solution (control), pretreatment with labetalol, fentanyl, or lidocaine 
significantly reduced seizure duration (P less than 0.05) and increased the 
frequency with which a second electrical stimulus was required. In contrast, 
esmolol pretreatment did not significantly affect seizure duration. Esmolol (1 
mg/kg), administered 1 min before induction of anesthesia, produced 
significant amelioration of the cardiovascular response to ECT with minimal 
effect on seizure duration. 
 In this study comparison of  Esmolol and Labetalol in attenuating 
hemodynamic responses after ECT was done.90 patients were divided 
randomly into 3 groups.Each group contains 30 patients.Patients in each 
group received saline or either bolus dose of  Esmolol 1mg/kg or Labetalol 
0.25mg/kg just after induction with propofol.ECT was given after 2 minutes 
of test drug. 
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 Heart rate, Systolic BP,Diastolic BP were recorded before ECT,1 
minute after test drug and 1,3,5,10 minutes after ECT.It was found that 
Esmolol 1mg/kg was significantly attenuates the hemodynamic responses by 
reducing the Heart rate,Systolic BP and Diastolic BP up to 3 minutes after 
ECT. Where as Labetalol reduces the Heart rate from 5 minutes to 10 
minutes, and reduces Systolic BP and Diastolic BP from 3 minutes to 10 
minutes. 
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DISCUSSION 
 Electroconvulsive therapy (ECT) is used to treat severe depression 
resistant to pharmacological treatment.It is used for the past 50 years.In the 
initial period ECT was given without anaesthesia.Now a days ECT is 
administered with anaesthesia to eliminate the advers events of the 
unmodified ECT.The goal of anaesthetist is to provide anaesthesia without 
affecting the therapeutic effects of ECT.The therapeutic effects of ECT is due 
to central nervous system activation,but the exact mechanism of the 
beneficial effects is not known.During ECT after application of electric 
current tonic clonic seizures occurs.During the period of tonic clonic seizures 
parasympathetic discharge occurs which may cause bradycardia or even 
asystole.But it lasts for few seconds(10-15 sec),which is followed by 
sympathetic discharge occurs.Sympathetic discharge is due to the release of 
adrenaline and noradrenaline.Adrenaline level increased 15 times and comes 
to normal level after 10 minutes of ECT.Noradrenaline level increases 3 
times and remains increased for twice as long.Peak level occurs at 60 sec 
after ECT. This leads to increases in Heart rate,Systolic BP,Diastolic BP and 
cardiac output.During ECT myocardial oxygen demand increases and 
myocardial oxygen supply decreases.SO, patients with comorbidities are at 
risk of developing ischemia or infarction.Cerebral blood flow and intracranial 
pressure also increases. 
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 During ECT intra ocular pressure and intragastric pressure increases.It 
is necessary to attenuate the hemodynamic responses after ECT.For that a 
short acting beta-blocker or drug that have both alpha and beta blocking 
property can be used to blunt the stress response caused by 
catecholamines.Mortality rate is 0.03% if patients with cardiovascular disease 
undergo ECT.Many drugs are used to attenuate the hemodynamic responses 
after ECT.These include antihypertensive drug including trimethaphan, 
nitroprusside,nitroglycerin,beta blockers like propranolol, alprenolol, 
esmolol,labetalol, alpha agonists like clonidine, dexmedetomidine, urapidil, 
and calcium channel blockers like nicardipine.There is no standard regimen 
to blunt the hemodynamic responses after ECT.The property of the ideal drug 
should be more convenient to the patient.It must be easily 
available,cheap,easy to prepare and administer,onset of action must be 
rapid.It should not produce any toxic effects and have minimal side effect. 
 Esmolol hydrochloride is an ultra-short acting,cardio selective beta 
blocker(beta 1).Its distribution half  life is 2 minutes.Elimination half life of 
Esmolol is 9 minutes. Esmolol is also more useful in attenuating the stress 
response during laryngoscopy and intubation and also used to reduce the 
stress intraoperatively and postoperatively.Labetolol is adrenergic receptor 
blocking agent with mild alpha1 and predominant beta-adrenergic receptor 
blocking actions.  
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 Ratio of alpha:beta blockade is 1:7 when it is administered 
intravenously and 1:3for PO administration. Labetalol onset of action is 2-5 
minutes with peak effect at 5-15 minutes.These properties like rapid onset of 
the drug makes the drug useful in attenuating the hemodynamic responses 
after ECT.It will take 10-20 minutes to decrease the adrenaline and 
noradrenaline level to normal after ECT. Hemodynamic changes occurs after 
ECT lasts for 10 minutes.After ECT for a period of ten minutes Esmolol and 
Labetolol take part in reducing the hemodynamic changes.It was found that 
Esmolol  dose of 1mg/kg was effective in attenuating the increase in Heart 
rate,Systolic BP,Diastolic BP up to 3 minutes but not effective in the later 
period of ECT(3-10 min).The time coinsides with the onset and peak time of 
the Esmolol.This results is similar to that found in study conducted by kovac 
et al.This study found that 0.25mg/kg Labetolol is not effective in attenuating 
the increase in mean Heart rate in the first 5 minutes and Systolic BP and 
Diastolic BP in the first 3 minutes.But Labetalol is effective in attenuating the 
Heart rate after 5-10 minutes of ECT and Systolic BP and Diastolic BP after 
3-10 minutes of ECT.The time coinsides with the onset and peak time of the 
Labetalol.This results is similar to that found in study conducted by  Castelli 
I& Steiner in 1995.  
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Demographic profile: 
 The mean age ,sex distribution, the BMI, ASA classification were 
comparable in all the three groups and there was no statistical difference 
between these groups. 
between these groups. 
CHANGES IN HEART RATE 
Comparison of Esmolol with Control group 
 In both Control and Esmolol group baseline mean heart rate was 
same.The difference between mean Heart rate was not statistically 
significant( P value=0.28).After 1 min of ECT the mean heart rate in Control 
group was 125.2 and where as in Esmolol group was 98.3.The difference 
between the mean heart rate was statistically significant(P value 
=<0.05).After 3 min of  ECT the mean heart rate in Control group was 137.5 
and in Esmolol group was 100.5.The difference in the mean heart rate 
between the Control group and Esmolol group was statistically significant(P 
value =0.0001).The mean heart rate in Control group after 5 minutes and 10 
minutes of ECT was 108.1 and 111.4 and in Esmolol group was109.0 and 
109.9.  
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 The difference between mean heart rate between the Control group and 
in Esmolol group after 5 and 10 minutes ECT was statistically insignificant(P 
value =0.44 and 0.22 respectively).This clearly shows that Esmolol was 
effective in attenuating the increase in heart rate in the immediate period that 
is 1 minute and 3 minutes after ECT but not effective in attenuating the rise 
in heart rate in the later period (5-10minutes after ECT).This results is similar 
to result of the study conducted by D O’Flaherty et al who found that 
esmolol is preffered to nitroglycerine to control the heart rate.   
Comparison of Labetalol with Control group 
 In both Control and Labetalol group baseline mean heart rate was 
same.The difference between mean Heart rate was not statistically 
significant( P value=0.105).After 1 min of ECT the mean heart rate in 
Control group was 125.2 and where as in Labetalol group was125.0.The 
difference between the mean heart rate was statistically insignificant(P value 
=0.88).After 3 min of  ECT the mean heart rate in Control group was 137.5 
and in Labetalol group was 136.0.The difference in the mean heart rate 
between the Control group and Labetalol group was statistically 
insignificant(P value =0.32).The mean heart rate in Control group after 5 
minutes and 10 minutes of ECT was 108.1 and 114.4 and in Labetalol group 
was 91.1 and 92.1.  
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 The difference between mean heart rate between the Control group and 
in Labetalol group after 5 and 10 minutes of ECT was statistically significant 
(P value =<0.0001).This clearly shows that Labetalol was  not effective in 
attenuating the increase in heart rate in the immediate period that is 1 minute 
and 3 minutes after ECT but effective in attenuating the rise in heart rate in 
the later period (5-10minutes after ECT).This results is similar to the study 
conducted by Jung Hee Ryu et al who compare the effects of labetelol and 
nicardepine in attenuating the stress response in ECT. 
CHANGES IN SYSTOLIC BP  
Comparison of Esmolol with Control group 
 In both Control and Esmolol group baseline Systolic BP was same.The 
difference between mean Systolic BP is not statistically significant( P 
value=0.95).After 1 min of ECT the mean Systolic BP in Control group was 
152.5 and where as in Esmolol group was121.5.The difference between the 
mean Systolic BP was statistically significant (P value =<0.0001).After 3 min 
of  ECT mean Systolic BP in Control group was 137.6 and in Esmolol group 
was 119.5.The difference in the mean Systolic BP between the Control group 
and Esmolol group was statistically significant(P value =<0.0001).The mean 
Systolic BP in Control group after 5 minutes and 10 minutes of ECT was 
138.3 and 131.9 respectively and in Esmolol group was135.4 and 132. 
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 The difference in mean Systolic BP between the Control group and in 
Esmolol group after 5 and 10 minutes of ECT was statistically insignificant(P 
value =0.18 and 0.88 respectively).This clearly shows that Esmolol was 
effective in attenuating the increase in Systolic BP in the immediate period 
that is 1 minute and 3 minutes after ECT but not effective in attenuating the 
rise in Systolic Blood Pressure in the later  period (5-10minutes after 
ECT).This results is similar to result of the study conducted by Castelli I& 
Steiner in 1995 who compared the effects of esmolol and labetalol in ECT 
for stress attenuation. 
Comparison of Labetalol with Control group 
 In both Control and Labetalol group baseline Systolic BP is same.The 
difference between mean Systolic BP was not statistically significant( P 
value(0.88).After 1 min of ECT the mean Systolic BP  in Control group was 
152.3 and where as in Labetalol group was150.3.The difference between the 
mean Systolic BP was statistically insignificant(P value =0.19).After 3 min of  
ECT the mean Systolic BP in Control group was 137.6 and in Labetalol 
group was 124.1.The difference in the mean Systolic BP between the Control 
group and Labetalol group was statistically significant(P value 
=<0.0001).The mean Systolic BP in Control group after 5 minutes and 10 
minutes of ECT was 138.3 and 131.9 and in Labetalol group was111.6 and 
112.3. 
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  The difference between Systolic BP between the Control group and in 
Labetalol group after 5 and 10 minutes of ECT was statistically significant(P 
value =<0.0001).This clearly shows that Labetalol was  not effective in 
attenuating the increase in Systolic BP in the immediate period that is 1 
minute and  after ECT but effective in attenuating in the rise Systolic BP in 
the later period (3-10minutes after ECT).This results is similar to result of 
study conducted by MB Weinger et al who found that labetalol is preffered 
over fentanyl in stress attenuation in ECT.    
CHANGES OF DIASTOLIC BP   
Comparison of Esmolol with Control group 
 In both Control and Esmolol group baseline Diastolic BP is same.The 
difference between mean Diastolic BP was not statistically significant( P 
value=0.84).After 1 min of ECT the mean Diastolic BP in Control group was 
91.5 and where as in Esmolol group was 81.1.The difference between the 
mean Diastolic BP was statistically significant(P value =<0.0001).After 3 
min of  ECT mean Diastolic BP in Control group was 93.1 and in Esmolol 
group was 81.1.The difference in the mean Diastolic BP between the Control 
group and Esmolol group was statistically significant(P value =<0.0001).The 
mean Diastolic BP in Control group after 5 minutes and 10 minutes of ECT 
was 86.0 and 85.1 respectively and in Esmolol group was 83.1 and 86.5. 
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 The difference in mean Diastolic BP between the Control group and in 
Esmolol group after 5 and 10 minutes of ECT was statistically insignificant(P 
value =0.19and 0.23 respectively).This clearly shows that Esmolol was 
effective in attenuating the increase in Diastolic BP in the immediate period 
that is 1 minute and 3 minutes after ECT but not effective in attenuating the 
rise in Diastolic BP in the later period (5-10minutes after ECT).This results is 
similar to result of the study conducted by Howie et al who defined the dose 
of esmolol in stress attenuation during ECT. 
Comparison of Labetalol with Control group 
 In both Control and Labetalol group baseline Diastolic BP is same.The 
difference between mean Diastolic BP was not statistically significant( P 
value=0.81).After 1 min of ECT the mean Diastolic BP  in Control group was 
91.5 and where as in Labetalol group was 91.8.The difference between the 
mean Diastolic BP was statistically insignificant(P value =0.86).After 3 min 
of  ECT the Diastolic BP in Control group was 93.1 and in Labetalol group 
was 80.5.The difference in the mean Diastolic BP between the Control group 
and Labetalol group was statistically significant(P value =<0.0001). 
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 The mean Diastolic BP in Control group after 5 minutes and 10 
minutes of ECT was 86.0 and 85.1and in Labetalol group was 74.1 and 73.7. 
The difference between Diastolic BP between the Control group and in 
Labetalol group after 5 and 10 minutes of ECT was statistically significant(P 
value =<0.0001).This clearly shows that Labetalol was  not effective in 
attenuating the increase in Diastolic BP in the immediate period that is 1 
minute and  after ECT but effective in attenuating the rise in Diastolic BP in 
the later period (3-10minutes after ECT).This results is similar to results of 
the study conducted by Sarvesh P singh et al who compared the effects of 
esmolol and labetalol in attenuation of hemodynamic responses in 
laryngoscopy and intubation. 
Side effects 
 one patient from the study group C,2 patients of  E group and 3 
patients of Lgroup developed bradycardia who were managed by I/V atropine 
bolus dose.3 patients developed hypotension ;1 from E and 2from L group 
which was managed by I/V fluids and intravenous ephedrine bolus.However 
the incidence of complications among all the three groups were statistically 
insignificant. 
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SUMMARY 
 This study was conducted in 90 patients undergoing Electroconvulsive 
therapy. 
 These patients were randomly divided into three groups with 30 
patients in each group.Age between 18 and 65 years,either sex,belonging to 
ASA I and II were included in this study.Patients with II degree AV 
conduction  block or greater,bradycardia Heart rate less than 50/min,systolic 
Blood pressure less than 90mmhg,asthmatic patients,patients with history of 
drug allergy,recent Myocardial infarction(with in 3 months) were excluded 
from this study. Patient was shifted to ECT room and secured large bore IV 
cannula.Baseline parameters were recorded and marked as “0”.All patients 
were preoxygenated with 100% O2.Patients were induced with inj.Propofol 
1-2mg/kg.Test drug was given immediately after induction and the time was 
noted. Group C received normal saline.Group E received Esmolol 1mg/kg IV 
and Group L received Labetalol 0.25mg/kg. Heart rate,Systolic BP and 
Diastolic BP werH recorded 1min after test drug and marked as X. 
Inj.succinylcholine 1mg/kg was given. Two minutes after test drug electric 
current was applied bitemporally.Visible tonic-clonic contractions shows the 
efficacy of ECT.Ventilation was assisted with 100% O2 until spontaneous 
respiration recovered.Heart rate,Systolic BP and Diastolic BP were recorded 
1,3,5 and 10 minutes after ECT and marked as A,B,C,D.  
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The following table shows the results obtained from this study 
 
PARAMETERS CONTROL ESMOLOL LABETALOL 
Mean age in years 35.2 31.5 33.5 
Mean weight in Kg 57.7 55.3 56.2 
Mean height in cm 158.2 156.9 155.2 
Mean baseline HR 101.1 100.7 99.1 
Mean HR 1 min after test drug 111.1 90.7 108.5 
Mean HR 1 min after ECT 125.2 98.3 128.0 
Mean HR 3 min after ECT 137.5 100.5 136.0 
Mean HR 5 min after ECT 108.1 109.0 91.1 
Mean HR 10 min after ECT 111.4 109.9 92.1 
Mean baseline SYS BP 131.6 131.7 131.3 
Mean SYS BP I min after test 
drug 
110.6 109.7 109.1 
Mean SYS BP 1 min after 
ECT 
152.5 121.5 150.3 
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Mean SYS BP 3 min after 
ECT 
137.6 119.5 124.1 
Mean SYS BP 5 min after 
ECT 
138.3 135.4 111.6 
Mean SYS BP 10 min after 
ECT 
131.9 132.2 112.3 
Mean baseline DIA BP  81.2 81.5 81.5 
Mean DIA BP 1 min after test 
drug 
84.1 72.1 82.5 
Mean DIA BP 1 min after 
ECT 
91.5 81.1 91.8 
Mean DIA BP 3 min after 
ECT 
93.1 82.1 80.5 
Mean DIA BP 5 min after 
ECT 
86.0 83.4 74.1 
Mean DIA BP 10 min after 
ECT 
85.1 86.5 73.7 
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The observation noted in this study are , 
1)By using the statistical analysis system,statistical analysis was done. t’  test 
was used to test the significance of difference between quantitative variables 
and  Yate’s and Fisher’s chi square tests for qualitative variables. A 'p' value 
less than 0.05 is taken to denote significant relationship. 
2)Demographic profile was similar in all the three groups and there 
was no statistical significant difference between these three groups . 
3) During ECT after application of electric current tonic clonic seizures 
occurs.During the period of tonic clonic seizures parasympathetic discharge 
occurs which may cause bradycardia or even asystole.But it lasts for few 
seconds(10-15 sec),which is followed by sympathetic discharge 
occurs.Sympathetic discharge is due to the release of adrenaline and 
noradrenaline.Adrenaline level increased 15 times and comes to normal level 
after 10 minutes of ECT.Noradrenaline level increases 3 times and remains 
increased for twice as long.Peak level occurs at 60 sec after ECT.This leads 
to increases in Heart rate,Systolic BP,Diastolic BP and cardiac output.  
Esmolol hydrochloride is an ultra-short acting,cardio selective beta 
blocker(beta 1).Its distribution half  life is 2 minutes.Elimination half life of 
Esmolol is 9 minutes.Peaks action at onset of action 1-2 minutes and peak 
effects at 3 minutes of administration.Labetolol is adrenergic receptor 
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blocking agent with mild alpha1 and predominant beta-adrenergic receptor 
blocking actions. Labetalol onset of action is 2-5 minutes with peak effect at 
5-15 minutes.These properties like rapid onset of the drug makes the drug 
useful in attenuating the hemodynamic responses after ECT. 
4)Esmolol significantly reduces the heart rate,systolic blood pressure and 
diastolic blood pressure from one to three minutes after ECT where as 
Labetalol did not produce any significant changes during that period. 
5)Labetalol significantly reduces the heart rate,systolic blood pressure and 
diastolic blood pressure from three to ten minutes after ECT where as 
Esmolol did not produce any significant changes during that period. 
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CONCLUSION 
 It is concluded that a dose of 1mg/kg of Esmolol is effective in 
attenuating the hemodynamic responses to ECT in the first 3 minutes whereas 
a dose of 0.25mg/kg of  Labetalol is effective in attenuating the responses to 
ECT in the period from 3-10 minutes. 
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PROFORMA 
NAME : 
I.P.NO : 
AGE & SEX : 
ASA : 
WEIGHT : 
HEIGHT : 
DATE& TIME OF ADMISSION : 
DATE& TIME OF DISCHARGE : 
DIAGNOSIS : 
HISTORY : 
HYPERTENSION 
OTHER SYSTEMIC ILLNESS 
ACUTE OR CHRONIC EYE DISEASE 
DRUG THERAPY 
ALLERGY TO DRUGS 
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CLINICAL EXAMINATION : 
PULSE RATE 
BLOOD PRESSURE 
SPO2 
PALLOR,ICTERUS,CLUBBING,CYANOSIS,LYMPHADENOPATHY, 
EDEMA CARDIOVASCULAR SYSTEM 
RESPIRATORY SYSTEM 
ORAL CAVITY 
AIRWAY 
NECK & SPINE 
BASIC INVESTIGATIONS:- 
HAEMOGLOBIN 
RENAL PARAMETERS & SERUM ELECTROLYTES, 
ECG 
CHEST X RAY PA VIEW 
BT, CT 
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RBS 
GROUP: 
TIME OF INDUCTION: 
TIME OF ADMINISTRATION OF TEST DRUG: 
 HEART 
RATE 
SYSTOLIC 
BP 
DIASTOLIC 
BP 
BASE LINE    
1 MIN AFTER TEST DRUG    
1MIN AFTER ECT    
3 MIN AFTER ECT    
5 MIN AFTER ECT    
10 MIN AFTER ECT    
 
COMPLICATIONS IF ANY: 
 
 
 
 
S.NO NAME GROUP AGE SEX ASA  WEIGHT    HEIGHT PR-O PR-X PR-A PR-B PR-C PR-D
SYS 
BP-O
SYS 
BP-X
SYS 
BP-A
SYS 
BP-B
SYS 
BP-C
SYS 
BP-D
DIA 
BP-O
DIA 
BP-X
DIA 
BP-A
DIA 
BP-B
DIA 
BP-C
DIA 
BP-D
SP02
1 SASIKALA CONTROL 34 FEMALE I 52 156 102 112 130 139 110 102 110 100 132 116 118 116 66 74 80 82 78 70 99
2 SUKUMAR CONTROL 38 MALE ii 48 157 100 110 126 137 106 110 122 116 148 128 130 120 72 76 82 84 82 74 99
3 MUNIYAMMAL CONTROL 40 FEMALE I 52 165 96 106 122 131 104 108 140 120 158 146 144 140 86 90 98 100 90 88 99
4 MANI CONTROL 32 MALE I 54 160 100 110 126 136 108 114 124 100 148 132 130 130 80 84 92 92 82 84 100
5 SRITHAR CONTROL 28 MALE I 48 159 104 114 120 140 110 114 122 108 146 130 128 122 76 82 90 92 82 80 99
6 SELVI CONTROL 26 FEMALE I 50 154 102 112 130 138 108 102 126 102 150 132 130 128 78 78 86 88 84 82 100
7 RAVI CONTROL 26 MALE I 54 159 104 114 120 140 110 116 138 114 156 142 140 136 84 84 92 94 88 88 99
8 BABU CONTROL 39 MALE II 57 158 96 106 122 133 102 106 140 120 160 146 148 136 90 94 100 102 84 94 100
9 MARI CONTROL 37 FEMALE I 51 156 106 116 134 142 112 108 132 110 156 144 146 136 82 84 90 92 86 86 99
10 IRULANDI CONTROL 42 MALE II 59 160 102 112 130 139 110 104 138 118 156 142 142 134 84 88 94 96 88 86 100
11 SATHYA CONTROL 18 FEMALE I 52 155 98 108 114 133 106 112 128 106 146 132 134 130 78 82 88 90 84 82 99
12 RAJASEKAR CONTROL 47 MALE I 74 158 106 116 134 141 112 120 140 118 158 144 144 138 84 88 84 86 90 88 99
13 VASANTHI CONTROL 39 FEMALE I 56 164 100 110 126 137 106 112 140 116 158 144 146 138 86 86 94 94 90 90 100
14 GOPI CONTROL 36 MALE I 52 160 102 112 130 136 108 114 132 110 150 140 140 134 82 88 92 98 88 86 99
15 RAJAM CONTROL 41 FEMALE ii 52 157 94 104 120 132 104 110 136 114 156 144 148 136 82 86 92 96 86 86 98
16 RAJESH CONTROL 38 MALE I 56 159 100 110 126 137 106 112 134 110 154 142 146 138 80 84 94 94 88 84 100
17 AMBAL CONTROL 28 FEMALE I 64 154 102 112 130 139 110 104 136 112 158 146 144 132 84 88 98 96 90 88 99
18 ARULRAJ CONTROL 32 MALE I 58 159 98 108 114 135 104 112 130 106 152 140 144 132 82 84 96 94 88 84 99
19 BHUVANA CONTROL 46 FEMALE II 72 156 96 106 122 132 104 112 138 108 156 138 136 136 84 88 96 98 86 88 98
20 BALAKUMAR CONTROL 28 MALE I 60 160 100 110 126 135 110 116 140 122 158 144 142 136 90 86 98 100 88 94 99
21 RAJESHWARI CONTROL 39 FEMALE I 56 157 104 114 120 140 110 116 138 114 162 150 148 134 86 92 98 100 86 90 100
22 MOHAN CONTROL 20 MALE I 57 158 98 108 114 136 108 112 136 110 156 138 148 132 82 86 94 96 86 86 99
23 JEYARAJ CONTROL 54 MALE II 62 155 100 110 126 137 106 112 138 120 158 140 138 140 84 88 98 100 90 88 99
24 SARASWATHI CONTROL 41 FEMALE I 62 163 102 112 130 139 110 122 134 100 160 144 142 134 86 90 96 98 92 90 100
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25 PRASATH CONTROL 26 MALE I 68 158 106 116 134 143 110 120 136 122 156 136 140 134 80 78 86 88 86 86 99
26 MAHALAKSHMI CONTROL 42 FAMALE I 58 153 102 112 130 139 110 104 130 108 154 134 138 132 82 80 86 88 88 86 98
27 KUMAR CONTROL 32 MALE I 70 158 104 114 120 138 112 118 126 104 146 134 132 130 78 80 88 90 84 82 99
28 KANNAN CONTROL 38 MALE I 63 168 102 112 130 139 108 108 130 108 154 134 140 132 78 84 94 92 84 84 100
29 SIVANAMMAL CONTROL 33 FEMALE I 56 153 102 112 130 139 112 104 124 102 144 132 130 130 80 82 90 94 86 84 100
30 PANDI CONTROL 35 MALE I 57 157 104 114 120 142 108 118 110 100 130 114 112 112 70 70 80 78 76 74 99
31 MAHARANI ESMOLOL 22 FEMALE I 42 156 102 92 98 100 102 110 112 100 108 106 116 114 66 62 68 70 82 82 99
32 CATHERINE ESMOLOL 26 FEMALE I 46 157 102 90 96 98 110 110 120 110 118 114 128 126 74 68 72 74 88 86 99
33 LAKSHMI ESMOLOL 40 FEMALE I 53 155 98 90 98 100 104 116 140 120 124 122 144 140 86 78 86 88 84 80 99
34 BALU ESMOLOL 20 MALE I 50 160 100 92 100 100 110 108 126 100 120 116 130 128 80 70 80 80 84 88 100
35 JOTHIBASU ESMOLOL 18 MALE I 48 159 98 90 100 102 116 106 122 108 118 114 126 124 78 70 76 76 86 88 99
36 MALLIKA ESMOLOL 24 FEMALE I 50 154 102 92 98 102 118 110 126 102 120 118 130 128 78 66 78 80 78 82 99
37 MURUGAN ESMOLOL 25 MALE I 44 159 104 94 98 100 104 112 138 114 122 120 142 136 84 78 82 80 82 80 99
38 VASANTHI ESMOLOL 39 MALE II 57 158 96 88 98 100 118 104 142 120 124 122 140 136 90 80 90 82 86 84 100
39 KAVITHA ESMOLOL 37 FEMALE I 51 156 106 96 98 98 106 114 130 110 122 120 140 136 82 72 82 90 80 92 99
40 MARIAPPAN ESMOLOL 42 MALE II 49 160 98 90 98 104 108 118 138 108 126 124 142 136 84 74 84 86 82 86 100
41 GANDHIMATHI ESMOLOL 19 FEMALE I 52 155 98 88 98 100 108 106 128 106 122 120 132 130 78 68 76 76 88 90 99
42 NARAYANAN ESMOLOL 47 MALE I 74 158 106 98 100 104 116 114 142 112 124 122 144 138 84 74 84 84 84 84 99
43 MUTHULAKSHMI ESMOLOL 39 FEMALE I 56 154 102 92 98 100 112 110 140 116 124 124 144 136 86 74 86 88 86 86 100
44 KARUNAKARAN ESMOLOL 26 MALE I 52 160 102 92 98 100 112 110 134 106 122 120 138 134 82 78 82 84 82 94 99
45 SHANTHI ESMOLOL 41 FEMALE I 49 157 104 86 94 96 104 112 136 110 126 124 140 136 84 74 82 82 86 88 98
46 DURAI ESMOLOL 27 MALE I 54 159 100 90 100 102 100 108 134 124 124 120 140 138 80 70 80 80 88 92 99
47 GOMATHI ESMOLOL 28 FEMALE I 56 154 98 92 102 104 108 106 136 110 124 124 140 134 84 74 84 84 82 86 99
48 SARAVANAN ESMOLOL 22 MALE I 58 159 98 90 100 102 104 106 128 106 122 120 138 132 82 70 82 82 82 90 99
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49 SUNDARI ESMOLOL 46 FEMALE II 72 156 96 86 98 100 106 114 138 108 126 124 138 136 84 70 84 86 86 88 98
50 RANJITH ESMOLOL 30 MALE I 60 160 100 90 102 106 104 108 140 122 124 122 140 136 88 74 90 90 82 82 99
51 RAJI ESMOLOL 29 FEMALE I 55 157 102 92 104 106 102 110 138 116 122 120 140 138 86 78 86 86 92 90 100
52 MATHAN ESMOLOL 20 MALE I 56 158 96 92 98 104 106 104 136 110 120 118 138 132 84 80 82 84 86 80 99
53 ARAYEE ESMOLOL 54 FEMALE II 62 155 102 86 90 92 108 102 138 108 124 122 136 138 84 70 84 84 88 92 99
54 FATHIMA ESMOLOL 31 FEMALE I 52 153 104 94 96 98 102 112 132 100 122 120 132 134 88 76 86 88 86 90 99
55 AYYAPPAN ESMOLOL 24 MALE I 68 158 106 96 96 98 106 114 136 122 124 122 136 134 80 70 80 82 88 82 99
56 KARPAGAM ESMOLOL 32 FAMALE I 58 153 98 88 98 100 114 106 130 108 124 122 134 132 82 72 82 82 82 90 98
57 ARASI ESMOLOL 32 FEMALE I 70 158 104 94 100 100 114 112 126 104 120 120 134 130 78 68 78 80 86 84 99
58 NAMBIRAJ ESMOLOL 38 MALE I 51 158 98 86 98 100 118 116 130 108 122 120 134 132 78 70 78 84 84 86 100
59 SUTHA ESMOLOL 33 FEMALE I 56 153 98 90 98 96 116 106 126 102 120 118 132 130 80 70 80 80 90 90 100
60 SENTHIL ESMOLOL 35 MALE I 57 157 104 84 98 102 114 112 110 100 108 106 114 112 70 86 70 72 86 84 99
61 SARATHA LABETOLOL 32 FEMALE I 44 156 100 106 116 136 88 90 108 106 156 104 102 102 66 82 82 72 62 60 99
62 KALYANI LABETOLOL 26 FEMALE I 56 157 106 104 118 138 90 92 122 116 154 108 110 118 72 84 82 72 66 64 98
63 BHUVANA LABETOLOL 40 FEMALE I 54 155 102 110 124 136 96 98 140 112 156 128 110 122 88 86 100 90 82 80 99
64 KALAIARASAN LABETOLOL 30 MALE I 50 160 100 106 128 138 94 92 124 110 154 116 112 102 80 80 92 76 70 68 100
65 KAVITHA LABETOLOL 18 FEMALE I 46 159 96 108 116 136 86 86 120 108 140 114 106 110 78 86 90 80 76 74 99
66 VALARMATHI LABETOLOL 24 FEMALE I 52 154 100 106 122 134 92 94 126 110 156 116 107 104 78 88 86 76 70 84 98
67 ANBARASU LABETOLOL 35 MALE I 46 152 92 108 124 140 86 86 138 110 158 128 116 116 86 78 94 84 78 78 99
68 XAVIER LABETOLOL 39 MALE II 59 158 94 104 126 136 90 92 140 114 152 130 116 122 90 80 100 90 84 82 100
69 CHINNATHAI LABETOLOL 37 FEMALE I 51 156 98 106 120 142 92 94 132 110 142 120 110 112 82 84 90 76 70 68 99
70 KALAIARASAN LABETOLOL 42 MALE II 51 154 96 108 132 134 90 92 138 112 154 132 118 120 84 88 96 84 80 78 100
71 PRIYA LABETOLOL 29 FEMALE I 54 155 94 100 120 134 88 90 128 106 144 118 110 108 78 82 86 80 74 86 99
72 RAJAN LABETOLOL 47 MALE ii 74 158 104 102 124 132 94 92 140 118 154 130 114 120 84 78 84 74 70 72 99
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73 MANJULA LABETOLOL 39 FEMALE I 58 154 92 108 128 138 86 86 140 110 144 130 118 118 86 84 94 84 78 76 100
74 VEERANAN LABETOLOL 26 MALE I 52 153 98 114 128 136 92 94 132 102 150 120 110 112 82 78 92 82 76 74 99
75 DEVI LABETOLOL 41 FEMALE iii 51 150 102 108 124 136 96 98 136 112 156 128 110 116 82 88 88 78 70 72 98
76 GOVINDAN LABETOLOL 37 MALE I 54 159 100 106 122 138 94 92 132 110 152 126 114 112 80 76 94 84 76 74 99
77 RADHA LABETOLOL 28 FEMALE I 56 154 102 112 130 140 90 92 136 112 146 128 112 114 84 82 98 78 72 70 98
78 JAYAKUMAR LABETOLOL 32 MALE I 56 159 94 110 128 138 90 92 130 106 152 124 108 112 82 80 96 72 70 68 99
79 THAMARAI LABETOLOL 46 FEMALE II 72 156 100 104 130 136 94 92 136 110 148 132 120 110 84 82 100 88 80 78 98
80 MANICKAM LABETOLOL 30 MALE I 60 150 102 108 124 138 96 98 140 122 152 130 122 124 90 84 98 88 84 82 99
81 THANGAM LABETOLOL 29 FEMALE I 55 157 100 106 128 132 92 94 138 110 150 140 124 116 88 82 98 88 82 80 100
82 PERUMAL LABETOLOL 20 MALE I 58 158 102 108 126 134 96 98 136 110 152 128 106 112 82 80 94 84 78 76 99
83 SIGAPPI LABETOLOL 54 FEMALE II 62 155 98 104 132 138 90 92 138 114 148 136 116 122 86 84 100 84 64 64 99
84 JOTHI LABETOLOL 31 FEMALE I 54 153 96 112 128 136 90 92 132 100 154 130 110 102 86 86 96 86 78 76 98
85 SHANKAR LABETOLOL 24 MALE ii 68 151 102 116 124 138 94 92 136 110 152 128 106 122 80 80 86 76 70 68 99
86 PREMA LABETOLOL 32 FAMALE I 58 153 106 114 126 134 86 86 130 108 148 130 112 108 82 82 86 76 70 76 98
87 PARVATHI LABETOLOL 32 FEMALE I 70 152 98 116 124 142 92 94 126 104 150 118 100 104 78 80 88 78 72 70 99
88 DHARMARAJ LABETOLOL 38 MALE ii 51 158 104 112 128 138 88 90 130 100 152 124 112 108 78 82 94 84 80 76 100
89 SHANKARI LABETOLOL 33 FEMALE I 56 153 96 116 124 136 90 92 124 102 146 122 108 102 80 88 90 80 74 72 98
90 ALLIRAJA LABETOLOL 35 MALE I 57 157 98 114 126 138 90 92 110 100 138 104 110 100 70 82 80 70 68 66 99
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